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INTRODUCTION 1,2 
There are certain conditions where it is desirable to extend the dosing interval of 
many pharmaceuticals while maintaining the initial plasma concentration achievable with 
conventional tablets. This would provide immediate and extended therapeutic effects and 
reduces the number of dosage necessary; they’re by making therapy more convenient. This 
can be done by formulating tablets containing two layers, one containing the immediate 
release layer and one containing the sustained release layer. Thus a Bi-layer tablet can 
achieve the initial plasma concentration achievable with conventional tablets and maintain 
for long time as sustained release tablets. 
Bi-layers tablet is defined as tablets consisting of two discrete zones consisting of 
same or different active pharmaceutical ingredients intended for therapeutic action. Bi-layer 
tablets consist of two layers 
1. Immediate release layer- contains loading dose  
2. Controlled release layer – contains maintenance dose. 
Immediate release layer of the dosage form containing the loading dose that delivers 
the entirely of its drug content at once after administration for the purpose of providing a 
rapid rise of drug concentration in the blood stream.   
Sustained release layer of the dosage form contains the maintenance dose that 
gradually release its drug content over a given period of time after administration for the 
purpose  of providing a constant concentration of drug in to the blood stream. 
The Blood Level Time Profile of a Bi-layer Tablet  
 
Figure No 1: A Blood Level Time Profile for an Ideal Bi-layer Tablet 
Reasons for Preparing Bi-layer Tablets 3: -  
1. To separate physically and chemically incompatible ingredients 
2. Two different drugs can be administered together which causes better control of 
disease and increase the patient compliance  
e.g Nasal decongestant and antihistamine  
3. To produce repeat action or prolonged action product. 
 
The immediate release layer achieves the therapeutic drug in the plasma and the 
sustained release layer maintained a steady state plasma concentration. 
 
Bi-layer Tablets: Quality and GMP-Requirements 4 
To produce a quality Bi-layer tablet, in a validated and GMP-way, it is important that 
the selected press is capable of: 
¾ Preventing capping and separation of the two individual layers that constitute the Bi-
layer tablet 
¾ Providing sufficient tablet hardness 
¾ Preventing cross-contamination between the two layers 
¾ Producing a clear visual separation between the two layers 
¾ High yield 
¾ Accurate and individual weight control of the two layers 
These requirements seem obvious but are not so easily accomplished. 
Kinetic Pattern of Drug Release 5, 6: It is assumed that the drug, which is to be 
incorporated in to an ideal Bi-layer tablet dosage form, confers upon the body, the 
characteristics of a one compartment open model. The basic kinetic design of such a product 
is represented: 
Kinetic Pattern of Drug Release required for Ideal Bi-layer Tablets:- 
 
 
 
 
 
To achieve a therapeutic concentration promptly in the body and then to maintain that 
concentration for a given period of time requires that the total drug in the dosage form consist 
of two portion, one that provide the initial priming or loading dose (Di) and one that provide 
the maintenance or sustained dose (Dm) 
The initial priming dose of drug Di is released rapidly in to the gastrointestinal fluids 
immediately following administration of the dosage form. The release dose is required to be 
absorbed in to the body compartment rapidly following first order kinetic process. The aim of 
the initial rapid release and subsequent absorption of the initial priming dose is the rapid 
attainment of a therapeutic concentration of the drug in the body. The priming dose provides 
a rapid onset of the desired therapeutic response in the patient. 
Following this period of rapid drug release, the portion Dm of drug remaining in the 
dosage form is released at a slow but defined rate. In order to maintain a constant plasma 
level of drug, the maintenance dose the dosage form according to zero order kinetics must 
release Dm. It thus follows that the rate of release of drug will remain constant and be 
independent of the amount of maintenance dose remaining in the dosage form an any given 
time  
 Two further conditions must be fulfilled in order to ensure that the therapeutic 
concentration of drug in the body remains constant. 
1. The zero order rate of release of the drug from the maintenance dose must be rate 
determining with respect to the rate at which the released drug subsequently absorbed 
in to the body. The kinetic of absorption of the maintenance dose will be 
characterized by the same zero order release rate constant  
2.  The rate at which the maintenance dose released from the dosage form and hence the 
rate of absorption of drug into body, must be equal to the rate of drug output from the 
body when the concentration of drug in the body is the required therapeutic value. 
 
In practice, the design of an ideal Bi-layer tablet is capable of releasing the 
maintenance dose at a precise controlled rate which is in mass balance with the rate of drug 
elimination corresponding to the required therapeutic concentration of the drug in the plasma, 
is difficult to achieve, also there are problems in achieving and maintaining dose of drug in 
the presence of all the variable physiological conditions associated with the gastrointestinal 
tract. 
CONSIDERATIONS FOR THE FORMATION OF SUSTAINED RELEASE 
FORMULATION 6: 
¾ If the active compound has a long half-life (over 6 hours), it is sustained on its own.  
¾ If the pharmacological activity of the active compound is not related to its blood 
levels, time releasing then has no purpose.  
¾ If the absorption of the active compound involves an active transport, the 
development of a time-release product may be problematic.  
¾ Finally, if the active compound has a short half-life, it would require a large amount 
to maintain a prolonged effective dose. In this case, a broad therapeutic window is 
necessary to avoid toxicity; otherwise, the risk is unwarranted and another mode of 
administration would be recommended. 
The difference between controlled release and sustained release is that controlled release is a 
perfectly zero order release; that is, the drug releases over time irrespective of concentration. 
Sustained release implies slow release of the drug over a time period. It may or may not be 
controlled release. 
 
Formulation: -  
For good quality tablets with sharp definition between the layers, special care must be 
taken as: -  
1. Dusty fines must be limited, fine smaller than 100# mesh should be kept at a 
minimum. 
2. Maximum granules size should be less than 16# mesh for a smooth, uniform scrape 
off at the die. 
3. Low moisture is essential if incompatibilities are used. 
4. Weak granules that break down easily must be avoided; excessive amount of 
lubricant, especially magnesium Stearate should be avoided for better adhesion of 
the layers. 
5. Formulation of multi layer tablet is more demanding than that of single layer tablets 
for this reason selection of additives is critical. 
 
Pharmacological Properties and Therapeutic uses: 
Oral hypoglycemic agents are commonly prescribed drugs that find utility in 
controlling the symptoms of diabetes in the 80% of patients having NIDDM. Since insulin 
resistance an impaired insulin secretion are key factors in the pathogenesis of NIDDM. 
Treatment should be directed toward restoring metabolic normality by improving insulin 
secretion and reducing insulin resistance. These goals are accomplished through the use of 
oral hypoglycemic agents. Specially the sulfonylurea. 
Mechanism (s) of Sulfonylurea Hypoglycemia: 
The sulfonylurea produces the hypoglycemia actions via several mechanisms that can 
be broadly sub-classified as pancreatic and extra-pancreatic:  
A. Pancreatic Mechanism: All sulfonylurea hypoglycemics inhibit the efflux of K+ (K+ 
channel blockers) from pancreatic β-cells via a sulfonylurea receptor, which may be 
closely linked to an ATP-sensitive K+-channel. The inhibition of efflux of K+ leads to 
depolarization of the β-cell membrane and as a consequence, voltage-dependent Ca+- 
channels on the β-cell membrane then open to permit entry of Ca+, the resultant 
increased binding of Ca+ to Calmodulin results in activation of kinases associated 
with endocrine secretory granules thereby promoting the exocytosis of insulin-
containing secretory granules:  
 
Fig No. 3 Pancreatic Mechanism of Sulfonylurea Hypoglycemia 
 
 
B. Extra-Pancreatic Mechanisms:  
 
The sulfonylurea also reduces serum glucagon levels possibly contributing to its 
hypoglycemic effects. The precise mechanism by which this occurs remains unclear 
but may result from indirect (secondary) inhibition due to enhanced release of both 
somastatin and insulin. 
Sulfonylurea may also potentiate insulin action at targeting tissues (Drug dependent 
characteristic). 
Glimepiride is a sulfonylurea ant diabetic agent, which decreases blood glucose 
concentrations. 
The primary mechanism of action of Glimepiride appears to be dependent on 
stimulating the release of insulin from functioning pancreatic beta cells. Glimepiride acts in 
concert with glucose by improving the sensitivity of beta cells to physiological glucose 
stimulus, resulting in insulin secretion in the rhythm of meals. In addition, extra pancreatic 
effects (e.g. reduction of basal hepatic glucose production and increased peripheral tissue 
sensitivity to insulin and glucose uptake) may also play a limited role in the activity of 
Glimepiride. 
In nonfasting diabetic patients, the hypoglycemic action of a single dose of 
Glimepiride persists for 24 hours. 
Evidence from in vitro and animal studies suggests that there is lower glucagons 
secretion with Glimepiride than glibenclamide and this may give rise to a prolonged 
reduction of blood glucose levels without increased plasma insulin levels. The clinical 
significance of these findings is yet to be clarified. A long-term, randomized, placebo 
controlled clinical trial demonstrated that Glimepiride therapy improves postprandial insulin/ 
C-peptide responses and overall glycaemic control without producing clinically meaningful 
increases in fasting insulin/ C-peptide levels. 
The efficacy of Glimepiride is not affected by age, gender or weight. Glimepiride 
therapy is effective in controlling blood glucose without deleterious changes in the plasma 
lipoprotein profile of patients. The physiological response to acute exercise (i.e. reduction of 
insulin secretion) is still present during Glimepiride therapy. 
 
Fig No. 4 Extra-Pancreatic Mechanism of Sulfonylurea Hypoglycemia 
Glimepiride and Metformin Hydrochloride Extended Release Tablets 
1. Description 
Bi-layer tablet contains two oral Anti-hyperglycaemic drugs Glimepiride and 
Metformin hydrochloride extended release used in the management of Type-2-diabetes 
(NIDDM). The primary mechanism of action of Glimepiride in lowering blood glucose 
appears to be dependent on stimulating the release of insulin from functioning pancreatic 
beta cells. Metformin hydrochloride decreases hepatic glucose production, decreases 
intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral 
glucose uptake and utilization. Hence, the combination of Glimepiride and Metformin 
extended release complements each other and provides better glycaemic control in 
management of Type 2 diabetes and probably in the prevention of its associated macro 
vascular and micro vascular complications. 
2. Pharmacology 
2.1 Pharmacodynamics 
Glimepiride 
The primary mechanism of action of Glimepiride in lowering blood glucose appears 
to be dependent on stimulating the release of insulin from functioning 2 pancreatic β-cells. In 
addition, extra pancreatic effects may also play a role in the activity of sulphonylureas such 
as Glimepiride. 
 
Metformin 
It improves glucose tolerance in patients with Type 2 diabetes (NIDDM), lowering 
both basal and postprandial plasma glucose. Metformin decreases hepatic glucose 
production, decreases intestinal absorption of glucose, and improves insulin sensitivity by 
increasing peripheral glucose uptake and utilization. 
2.2 Pharmacokinetics 
2.2.1 Absorption 
Glimepiride 
Glimepiride show significant absorption with NIDDM patients within 1 hour after 
administration and peak drug levels (Cmax) at 2 to 3 hours. When Glimepiride was given with 
meals, the mean Tmax (time to reach Cmax) was slightly increased (12%) and the mean Cmax 
and AUC (area under the curve) were slightly decreased (8% and 9%, respectively). 
Metformin extended release 
The absolute bioavailability of a Metformin 500-mg tablet given under fasting 
conditions is approximately 50-60%. Following a single oral dose of Metformin extended 
release; Cmax is achieved with a median value of 7 hours and a range of 4 hours to 8 hours. 
Peak plasma levels are approximately 20% lower compared to the same dose of Metformin 
immediate release, however, the extent of absorption (as measured by AUC) is similar to 
immediate release. Peak plasma levels are approximately 0.6, 1.1, 1.4, and 1.8 μg/mL for 
500, 1000, 1500, and 2000 mg once-daily doses, respectively. After repeated administration 
of extended release, Metformin did not accumulate in plasma.  
2.2.2 Distribution 
Glimepiride 
After intravenous (IV) dosing in normal subjects, the volume of distribution (Vd) was 
8.8 L (113 mL/kg), and the total body clearance (CL) was 47.8 mL/min. Protein binding was 
greater than 99.5%. 
Metformin extended release 
Distribution studies with Metformin extended release have not been conducted. 
Metformin is negligibly bound to plasma proteins, in contrast to sulphonylureas, which are 
more than 90% protein bound.  
2.2.3 Metabolism 
Glimepiride 
Glimepiride is completely metabolized by oxidative biotransformation after either an 
IV or oral dose. The major metabolites are the cyclohexyl hydroxy methyl derivative (M1) 
and the carboxyl derivative (M2). Cytochrome P450 II C9 has been shown to be involved in 
the biotransformation of Glimepiride to M1. M1 is further metabolized to M2 by one or 
several cytosolic enzymes. 
Metformin extended release 
Metabolism studies with Metformin extended release have not been conducted. 
2.2.4 Excretion 
Glimepiride 
When Glimepiride was given orally, approximately 60% of the total radioactivity was 
recovered in the urine in 7 days and M1 (predominant) and M2 accounted for 80-90% of that 
recovered in the urine. Approximately 40% of the total radioactivity was recovered in faeces 
and M1 and M2 (predominant) accounted for about 70% of that recovered in faeces. No 
parent drug was recovered from urine or faces.  
After IV dosing in patients, no significant biliary excretion of Glimepiride or its M1 
metabolite has been observed. 
Metformin 
Metformin is excreted unchanged in the urine and does not undergo hepatic 
metabolism or biliary excretion. Renal clearance of Metformin is approximately 3.5 times 
greater than creatinine clearance, which indicates that tubular secretion is the major route of 
Metformin elimination. Following oral administration, approximately 90% of the absorbed 
drug is eliminated via the renal route within the first 24 hours, with a plasma elimination 
half-life of approximately 6.2 hours.  
Dosage and Administration 
Dosage should be individualized on the basis of both effectiveness and tolerance. The 
combination should be given once daily with meals and should be started at a low dose. The 
initial recommended dose is one tablet once daily with breakfast or first main meal of the 
day.  
Maximum Recommended Dose:  
The maximum recommended dose for Glimepiride is 8 mg daily. The maximum 
recommended daily dose for Metformin extended release is 2000 mg in adults. 
CONTRAINDICATIONS 
¾ Renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 
mg/dL [males], ≥ 1.4 mg/dL [females] or abnormal creatinine clearance), which may 
also result from conditions such as cardiovascular collapse (shock), acute myocardial 
infarction, and septicemia. 
¾ Congestive heart failure requiring pharmacologic treatment. 
¾ Known hypersensitivity to this product or any of its components. 
¾ Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without 
coma. Diabetic ketoacidosis should be treated with insulin. 
¾ Patients undergoing radiologic studies involving intravascular administration of 
iodinated contrast materials, because use of such products may result in acute 
alteration of renal function. 
 
STORAGE: Store in a cool and dry place. 
Scope and Objective of the Study 
Objective of the study is to formulate Metformin and Glimepiride in Bi-layer tablet 
dosage form and evaluate different process Parameters. As Metformin and Glimepiride have 
more solubility and absorption in intestine. 
Literature survey reveals that several formulation methods of Bi-layer tablet such as 
Wet Granulation and Dry Granulation have been reported for Formulation of Metformin and 
Glimepiride. Most of reported methods for estimation of Metformin and Glimepiride are Wet 
Granulation. But the formulation has been developed by Direct Compression Method in 
place of Wet and Dry granulation  
  To achieve this goal, various prototype trials were taken and evaluated with respect to 
the various quality parameters such as Bulk Density, Sieve Analysis, Drug Uniformity, and 
Dissolution. 
Presently many brands are available in market, but present study carried out for 
developing of Metformin and Glimepiride Bi-layer tablets as generic product, which is 
cheaper, safe and better than other marketed products.  
Under this consideration, the overall objective of present work is: 
¾ Pre formulation study of Metformin and Glimepiride (i.e. API)  
¾ Selection of excipients which are stable and compatible with API  
(by Carrying out Drug-excipients compatibility study) 
¾ Formulation and development of conventional dosage form. 
¾ To study the effect of variation in different processing parameters on final 
formulation 
To Plan for Scale up Batch 
PLAN OF WORK 
To achieve this objective, the following plan of work was made. 
1. Literature Survey 
2. Analysis of Innovator Tablets 
(a) Glycomet GP-1mg (USV) 
(b) Gluconorm-G1 (Lupin) 
3. Preformulation Study  
(a) Compatibility Study 
(b) API Characterization  
4. Formulation and Evaluation of Tablet 
(I)  Pre-compression parameters  
(a) Loss on Drying. 
(b) Density Analysis 
(c) Compressibility Index and Hausner’s Ratio. 
(d) Sieve Analysis 
(II)  Post- compression Parameters. 
(a) Physical Appearance  
(b) Weight Variation  
(c) Thickness 
(d) Hardness 
(e) Friability 
(f) Disintegration Test 
(g) In-vitro Dissolution Study 
(h) Drug content Uniformity Test. 
5. Comparison with Reference Listed drug  
6. Stability Study of the Formulation  
7. Plan of Scale Up-Batch. 
 
 
 
Literature Survey 
1. H.O. Ammar, H.A. Salama14, et. al., Glimepiride is one of the third generation 
sulfonylureas used for treatment of type 2-diabetes. Poor aqueous solubility and slow 
dissolution rate of the drug lead to irreproducible clinical response or therapeutic 
failure in some cases due to subtherapeutic plasma drug levels. Consequently, the 
rationale of this study was to improve the biological performance of this drug 
through enhancing its solubility and dissolution rate. Phase solubility diagrams 
revealed increase in solubility of the drug upon cyclodextrin addition. In conclusion, 
the association of water soluble polymers with Glimepiride–CyD systems leads to 
great enhancement in dissolution rate, increased duration of action and improvement 
of therapeutic efficacy of the drug. 
 
2. Lian-Dong Hu., Yang Liu15., et. al., Metformin hydrochloride (MH) sustained-
release pellets were successfully prepared by centrifugal granulation. Seed cores 
preparation, drug layering, talc modification and coating of polymeric suspensions 
were carried out in a centrifugal granulator. Talc modification was performed before 
coating in order to overcome the high water solubility of metformin. The influence 
of surface modification by talc, the effects of Eudragit_ types and ratios, as well as 
the correlation between in vitro release and in vivo absorption. Combined use of two 
Eudragit_ polymers with different features as coating materials produced the desired 
results. Restricted delivery of metformin hydrochloride to the small intestine from 
differently coated pellets resulted in increased relative bioavailability and a sustained 
release effect. The adoption of several different pH dissolution media established a 
better relationship between the in vitro release and in vivo absorption of the 
sustained-release pellets.  
 
3. G. Di Colo, S. Falchi, Y. Zambito16, Compressed matrix tablets based on pH-
sensitive poly(ethylene oxide)–Eudragit L100 compounds have shown in vitro a 
compliance with the above requirement. The polymer compounds were prepared by 
a coevaporation process. The release pattern of Metformin hydrochloride from 
matrices depended on the PEO–EUD L ratio in the coevaporate. The 1:1 (w/w) ratio 
was unable to control Metformin hydrochloride release in simulated gastric fluid 
(SGF, pH 1.2), because the matrix material was excessively hydrophilic. 
Nevertheless, the release rate in SGF could be modulated by increasing the EUD L 
fraction in the coevaporate. With a PEO (M , 400 kDa)–EUD L (1:2, w/w) ratio the 
percent dose released in 2 h to SGF, where the coevaporate was insoluble, was 
around 23 or 50% with 10 or 20% loading dose. 
 
4. Shweta Arora, Rakesh K. Sharma17, et., al., Various grades of low-density 
polymers were used for the formulation of this system. They were prepared by 
physical blending of Metformin and the polymers in varying ratios. The formulation 
was optimized on the basis of in vitro buoyancy and in vitro release in simulated fed 
state gastric fluid (citrate phosphate buffer pH 3.0). Effect of various release 
modifiers was studied to ensure the delivery of drug from the HBS capsules over a 
prolonged period. Capsules prepared with HPMC K4M and ethyl cellulose gave the 
best in vitro percentage release and were taken as the optimized formulation. By 
fitting the data into zero order, first order and Higuchi model it was concluded that 
the release followed zero order release, as the correlation coefficient (R2 value) was 
higher for zero order release. It was concluded from R2 values for Higuchi model 
that drug release followed fickian diffusion mechanism. There was an increase in 
AUC in optimized HBS capsules of metformin when compared with immediate 
release formulation. 
 
5. Ganesh Rajput, Dr. Jayvadan Patel18., et. al.  The present investigation is aimed to 
formulate floating tablets of Metformin hydrochloride using an effervescent 
approach for gastro retentive drug delivery system. Floating tablets were prepared 
using directly compressible method using polymers HPMC K 100M and HPMC K 
4M for their gel-forming properties. Formulations were optimized using optimized 
polymers viscosity of HPMCK4M and HPMCK100M mixture. It was concluded that 
polymer viscosity had major influence on drug release from hydrophilic matrix 
tablets as well as on floating lag time. When polymer viscosity increase the 
similarity factor f2 was increased hence, it concluded that the polymer viscosity 
affected the similarity factor f2. The similarity factor f2 was carried out for 
optimized batch and the theoretical dissolution profile. The different ratios of HPMC 
K 4M and HPMC K 100M were evaluated to achieve apparent viscosity to 66633 
cps. The optimized batch showed the highest f2=82 value, it contained 37.34mg of 
HPMC K 4M and 212.66mg of HPMC K100M. 
6. Jingshu Piao, Ji-Eun Lee19., Mucoadhesive polymer-coated pellets containing 
metformin hydrochloride were prepared by the powder-layering technique using a 
centrifugal fluidizing (CF)-granulator. Four high-viscosity polymers were applied to 
make the pellets: 1) hydroxymethylcellulose (HPMC), 2) sodium alginate (Na-Alg), 
3) HPMC/Carbopol, and 4) sodium carboxylmethylcellulose (Na-CMC). The 
physical crushing test, mucoadhesive test, zeta-potential test, in vitro release study 
and observation of gastroretention state of the dosage form were performed to 
investigate the pellets. The strong adhesive interaction between the Na-CMC-coated 
pellets and the mucin disc was obtained by mucoadhesive test. Na-Alg was most 
effective among the polymers used in changing the value of zeta potential of the 
mucin solution by the interaction between a polymer and a mucin particle. Results 
from drug dissolution study showed that over 95% of the drug from all the four 
pellets was released before 2 h, while Na-CMC- and Na-Alg-coated pellets showed a 
moderate sustained-release in SGF (simulated gastric fluid) and SIF (simulated 
intestine fluid), respectively. In conclusion, Na-CMC and Na-Alg seem to be 
promising candidates for mucoadhesive formulation and further studies to improve 
the sustained-release property are underway for achieving the ultimate goal of once-
a-day formulation of metformin hydrochloride.  
 
7. Uttam Mandal, Tapan Kumar Pal20, The emerging new fixed dose combination of 
Metformin hydrocholride (HCl) as sustained release and glipizide as immediate 
release were formulated as a bilayer matrix tablet using hydroxy propyl methyl 
cellulose (HPMC) as the matrix-forming polymer, and the tablets were evaluated via 
in vitro studies. Three different grades of HPMC (HPMC K 4M, HPMC K 15M, and 
HPMC K 100M) were used. All tablet formulations yielded quality matrix 
preparations with satisfactory tableting properties. In vitro release studies were 
carried out at a phosphate buffer of pH 6.8 with 0.75% sodium lauryl sulphate w/v 
using the apparatus I (basket) as described in the United States Pharmacopeia (2000). 
The release kinetics of Metformin were evaluated using the regression coefficient 
analysis. There was no significant difference in drug release for different viscosity 
grade of HPMC with the same concentration. Tablet thus formulated provided 
sustained release of Metformin HCl over a period of 8 hours and glipizide as 
immediate release. 
8. Fiona Palmer, Marina Levina and Ali Rajabi-Siahboomi21., Extended release 
(ER) formulation of metformin hydrochloride (HCl) presents the formulator with 
significant challenges due to its poor inherent compressibility, high dose and high 
water solubility. This study investigates the possibility for development of a direct 
compression ER matrix tablet using hypromellose. 
 
9. T. Kiran, M.Sadanandam22, et.al., Surface solid dispersions using water-insoluble 
carriers like crospovidone, croscarmellose sodium, sodium starch glycolate, pre-
gelatinized starch, potato starch and Avicel PH 101 were investigated to enhance the 
dissolution rate of the glimepiride, a poorly water insoluble drug. The effect of 
various carriers on dissolution profile was studied using presence absence model. 
The surface solid dispersion on crospovidone with drug to carrier ratio of 1:19 
showed highest dissolution rate with the dissolution efficiency of 81.89% in 
comparison to pure drug (22.88%) and physical mixture (35.96%). The surface solid 
dispersion on crospovidone was characterized by powder X-ray diffractometry, 
differential scanning calorimetry, Fourier transform infrared spectroscopy, gas 
chromatography and scanning electron microscopy. The optimized dispersion was 
formulated into tablets by wet granulation method. These tablets, apart from 
fulfilling the official and other specifications, exhibited higher rates of dissolution 
and dissolution efficiency values. 
10. Ilic, R. Dreu, S. Srcic23, et. al.,Drug-free microparticles were prepared using a spray 
congealing process with the intention of studying the influence of processing 
parameters. By varying the atomizing pressure and liquid feed rate, microparticles 
with median sizes (d(0.5)) from 58 to 278 μm were produced, with total process yields 
ranging from 81% to 96%. An increased liquid feed rate was found to increase 
microparticle size, and higher atomizing pressures were found to decrease 
microparticle size. Greater change in microparticle size was achieved by varying 
atomizing pressure, which can be considered a dominant process parameter 
regarding microparticle size. In addition, microparticles with glimepiride, a model 
poorly water-soluble drug, were prepared by spray congealing using three different 
hydrophilic meltable carriers: Gelucire 50/13, poloxamer 188, and PEG 6000. 
Spherical microparticles with relatively smooth surfaces were obtained, with no drug 
crystals evident on the surfaces of drug-loaded microparticles. XRPD showed no 
change in crystallinity of the drug due to the technological process of microparticle 
production. All glimepiride loaded microparticles showed enhanced solubility 
compared to pure drug; however, Gelucire 50/13 as a carrier represents the most 
promising approach to the dissolution rate enhancement of glimepiride. The 
influence of storage (30 °C/65% RH for 30 days) on the morphology of 
glimepiride/Gelucire 50/13 microparticles was studied, and the formation of leaf-like 
structures was observed (a “blooming” effect) 
 
11 Uttam Mandal and Tapan Kumar Pal24, The emerging new fixed dose 
combination of Metformin hydrochloride (HCl) as sustained release and glipizide as 
immediate release were formulated as a bilayer matrix tablet using hydroxy propyl 
methyl cellulose (HPMC) as the matrix-forming polymer, and the tablets were 
evaluated via in vitro studies. Three different grades of HPMC (HPMC K 4M, 
HPMC K 15M, and HPMC K 100M) were used. All tablet formulations yielded 
quality matrix preparations with satisfactory tableting properties. In vitro release 
studies were carried out at a phosphate buffer of pH 6.8 with 0.75% sodium lauryl 
sulphate w/v using the apparatus I (basket) as described in the United States 
Pharmacopeia (2000). The release kinetics of Metformin was evaluated using the 
regression coefficient analysis. There was no significant difference in drug release 
for different viscosity grade of HPMC with the same concentration. Tablet thus 
formulated provided sustained release of Metformin HCl over a period of 8 hours 
and glipizide as immediate release. 
 12 Ouyang Defang, Pan Weisan25, et. al., A system that can deliver multi-drugs at a 
prolonged rate is very important to the treatment of various chronic diseases such as 
diabetes, asthma, and heart disease. Two controlled-release systems, which exhibited 
similar release profiles of Metformin and glipizide, i.e., elementary osmotic pump 
tablets (EOP) and bilayer hydrophilic matrix tablet (BT), were designed. The effects 
of pH and hydrodynamic conditions on drug release from two formulations were 
investigated. It was found that both drug releases from EOP were not sensitive to 
dissolution media pH and hydrodynamics change, while the release of glipizide from 
BT was influenced by the stirring rate. Moreover, in vivo evaluation was performed, 
relative to the equivalent dose of conventional metformin tablet and glipizide tablet, 
by a three-crossover study in six Beagle dogs. Cumulative percent input in vivo was 
compared to in vitro release profiles. The linear correlations of metformin and 
glipizide between fraction absorbed in vivo and fraction dissolved in vitro were 
established for EOP—a true zero-order release formula, whereas only nonlinear 
correlations were obtained for BT. In conclusion, drug release from EOP was both 
independent of in vitro and in vivo conditions, where the best sustained release effect 
was achieved, whereas the in vitro dissolution test employed for BT needed to be 
further optimized to be biorelevant. 
 
13 Sam Solomon, Senthamil Selvan26, et. al., The aim of this study was to design an 
oral sustained release matrix tablet of Metformin HCl and to optimize the drug 
release profile using response surface methodology. Tablets were prepared by non 
aqueous wet granulation method using HPMC K-15 M as matrix forming polymer. A 
central composite design for 2 factors at 3 levels each was employed to 
systematically optimize drug release profile .HPMC K 15 M ((X1) and PVP K 30 
(X2) were taken as the independent variable. The dependent Variables selected were 
% of drug released in 1 hr. (rel1hr), % of drug released in 8 hrs (rel 8hr) and timer 50% 
drug release (t50%). Contour plots were drawn, and optimum formulations were 
selected by feasibility and grid search. The formulated tablets followed Higuchi drug 
release kinetics and diffusion was the dominant mechanism of drug release, resulting 
in regulated and complete release within 8hrs. the polymer (HPMC K15M) and 
binder (PVP K 30) had significant ((P<0.05), Validation of optimization study, 
performed using 8 confirmatory runs, indicated very high degree of prognostic 
ability of response surface methodology, with mean percentage error (.S.D.) 
0.0437+0.3285. Besides unraveling the effect of the 2 factors on the in vitro drug 
release, the study helped in finding the optimum formulation with sustained drug 
release. 
 
14 Ashutosh Mohapatra, Mukesh C Gohel27, et. al., Metformin hydrochloride is an 
orally administered antihyperglycemic agent, used in the management of non insulin 
dependent (type-2) diabetes mellitus. Difficulty in swallowing (dysphagia) is 
common among all age group, especially in elderly and pediatrics. Unfortunately, a 
high percentage of patients suffering from type -2 diabetes are elderly people 
showing dysphasia. In this study, orally disintegrating tablets were prepared using 
direct compression and wet granulation method. First the tablets of Metformin were 
prepared using starch rx1500 and microcrystalline cellulose by direct compression. 
The tablets showed erosion behavior rather than disintegration. Then lactose was 
incorporated which created pores to cause burst release of drug. But these tablets did 
not give good mouth feel. thus pearlitol SD200(spray dried mannitol) was used to 
prepare tablets (LMCT 3 and MP 13) not only exhibited desired mouth feel but also 
disintegration time, invitro dispersion time, water absorption ratio, and in vitro drug 
release. All the batches contained 15% starch 1500 and 4% of croscarmellose 
sodium, the optimization bathes prepared by direct compression and wet granulation 
showed 85 % drug release at 4 min and 8 min, respectively. The strong saline and 
slight bitter taste of the drug masked using non nutritive sweetener and flavor   
 
 
DRUG PROFILE 
METFORMIN 
Description  : A Biguanide hypoglycemic agent used in the treatment of  
non-Insulin-dependent diabetes mellitus not responding to 
dietary modification. Metformin improves glycemic control by 
improving insulin sensitivity and decreasing intestinal 
absorption of glucose 
Drug Category : Hypoglycemic Agents 
Empirical Formula : C4H11N5 
Molecular Weight : 129.1636 
IUPAC Name  : 3-(diaminomethylidene)-1,1-dimethylguanidine 
Half Life  : 6.2 hours 
Chemical Structure :  
 
 
 
 
Physical Properties of API 
Melting Point  : 223-226 oC 
State   : Solid 
Solubility  : Freely soluble as HCl salt in water 
 
Pharmacological Parameters 
Drug category  : Hypoglycemic Agents 
Route of administration : Oral 
Pharmacology  : Metformin is an Anti-hyperglycemic agent, which  
improves glucose tolerance in patients with Type 2 
diabetes, lowering both basal and postprandial plasma 
glucose. Metformin is not chemically or 
pharmacologically related to any other classes of oral 
Anti-hyperglycemic agents. Unlike sulfonylureas, 
Metformin does not produce hypoglycemia in either 
patients with Type 2 diabetes or normal subjects and 
does not cause hyperinsulinemia. With Metformin 
therapy, insulin secretion remains unchanged while 
fasting insulin levels and daylong plasma insulin 
response may actually decrease. 
Mechanism of Action : Metformin pharmacologic mechanisms of action  
are different from other classes of oral 
antihyperglycemic agents. Metformin decreases hepatic 
glucose production, decreases intestinal absorption of 
glucose, and improves insulin sensitivity by increasing 
peripheral glucose uptake and utilization. 
Absorption   : Absorbed over 6 hours, bioavailability is 50 to 60%  
under fasting conditions. Food delays absorption. 
Protein Binding  : Metformin is negligibly bound to plasma proteins. 
Biotransformation  : Metformin is not metabolized 
Drug Interactions  :   
DRUG PROFILE 
GLIMEPIRIDE 
Description  : Glimepiride is the first III generation sulphonyl urea it is a  
very potent sulphonyl urea with long duration of action. 
 
Category  :  Sulfonylureas, Anti-Arrhythmia Agents, Hypoglycemic  
Agents, Immunosuppressive Agents,  
Empirical Formula : C24H34N4O5S 
Molecular Weight : 490.6160 
IUPAC Name  : 3-ethyl-4-methyl-N-[2-[4-[(4-methylcyclohexyl)  
carbamoylsulfamoyl] phenyl] ethyl]-2-oxo-5H-pyrrole-1- 
carboxamide 
Half Life  : 5 hours 
Chemical Structure : 
 
 
 
Physical Properties of API 
Drug Interaction 
           Cimetidine           : Cimetidine increases the effect of Metformin 
           Glucosamine        : Possible hyperglycemia 
Color & Appearance :  It is a white, Odorless, crystalline powder 
Melting Point   : 207 oC 
State    : Solid 
Solubility   : Insoluble in water and methanol  
pKa    :  6.2 
 
Pharmacological Parameters 
Drug category  : Sulfonylurea agent 
Route of administration : Oral 
Pharmacology  : Glimepiride is a "second-generation" sulfonylurea  
agent. It is used with diet to lower blood glucose by 
increasing the secretion of insulin from pancreas and 
increasing the sensitivity of peripheral tissues to insulin. 
Mechanism of Action : Glimepiride is lowering blood glucose by  
stimulating the release of insulin from functioning 
pancreatic beta cells, and increasing sensitivity of 
peripheral tissues to insulin. It binds to ATP-sensitive 
potassium channel receptors on the pancreatic cell 
surface, reducing potassium conductance and causing 
depolarization of the membrane. Membrane 
depolarization stimulates calcium ion influx through 
voltage-sensitive calcium channels. This increase in 
intracellular calcium ion concentration induces the 
secretion of insulin. 
Absorption   : Completely (100%) absorbed orally 
Protein Binding  : Over 99.5% bound to plasma protein. 
Drug Interactions  :   
Drug Interaction 
Cyclosporine The sulfonylurea increases the effect of cyclosporine 
Glucosamine Possible hyperglycemia 
Ketoconazole Ketoconazole increases the effect of rosiglitazone 
Repaglinide Similar mode of action - questionable association 
Rifampin 
Rifampin reduces levels and efficacy of rosiglitazone, rifampin 
decreases the effect of sulfonylurea 
HYDROXYPROPYL METHYL CELLULOSE 
 
Chemical Name  : Cellulose hydroxyl propyl Methyl ether 
Molecular weight  : 10,000–1,500,000.  
Structural Formula  : 
 
 
 
 
Functional Categories :  Coating 
agent; film-former; rate- controlling  
polymer for sustained release; stabilizing agent; 
suspending agent; tablet binder; viscosity-increasing 
agent. 
Descriptions   : Hypromellose is an odorless and tasteless, white or  
creamy white fibrous or granular powder. 
 
TYPICAL PROPERTIES 
 
Acidity/alkalinity  :  pH 5.5–8.0 for a 1% w/w aqueous solution. 
Ash    :  1.5–3.0%, depending upon the grade and viscosity. 
Auto ignition temperature :  360ºC 
Density (Bulk)  :  0.341 g/cm3 
Density (Tapped)  :  0.557 g/cm3 
Density (True)  :  1.326 g/cm3 
Melting Point   :  Browns at 190–200ºC; chars at 225–230ºC. 
    Glass transition temperature is 170–180ºC. 
Specific Gravity  :  1.26 
Solubility   : Soluble in cold water, insoluble in chloroform,  
ethanol (95%), and ether 
Moisture content  : Hypromellose absorbs moisture from the  
atmosphere the amount of water absorbed depends 
upon the initial moisture content and the temperature 
and relative humidity of the surrounding air.  
Viscosity (dynamic)  : Solutions prepared Hypromellose 347 using organic  
solvents tend to be more viscous; increasing 
concentration also produces more viscous solutions 
Stability   : Solutions are stable at pH 3–11 
Storage Conditions  : 1. Hygroscopic after drying, 
2. Increasing temperature reduces the viscosity. 
Safety    : 1. Nontoxic and Non-irritant material,  
2. Excessive oral consumption has laxative effect. 
 
Applications in Pharmaceutical Formulation or Technology: 
 
¾ Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.  
¾ In oral products, Hypromellose is primarily used as a tablet Binder (2-5% w/w), in 
film-coating, and as a matrix for use in extended-release tablet formulations.  
¾ High-viscosity grades may be used to retard the release of drugs from a matrix at 
levels of 10–80% w/w in tablets and capsules.  
¾ Hypromellose is also used as a suspending and thickening agent in topical 
formulations.  
¾ Hypromellose at concentrations between 0.45–1.0% w/w may be added as a 
thickening agent to vehicles for eye drops and artificial tear solutions.  
¾ Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent in 
topical gels and ointments.  
¾ It is also widely used in cosmetics and food products. 
 
Table No. 1 MATERIALS USED 
Sr.No. Name Category Suppliers of material 
Sustained Release Layer 
1. Metformin HCl API Morepen Labs.Ltd.Parwanoo 
2. Methocel K100 M Binder Morepen Labs.Ltd.Parwanoo 
3. Microcrystalline cellulose Filler Morepen Labs.Ltd.Parwanoo 
4. Colloidal Silicon Dioxide Glidant Morepen Labs.Ltd.Parwanoo 
5. Magnesium Stearate Lubricant Morepen Labs.Ltd.Parwanoo 
Immediate Release Layer 
1. Glimepiride API Morepen Labs.Ltd.Parwanoo 
2. Starch 1500 Multi functional 
excipient 
Morepen Labs.Ltd.Parwanoo 
3. Microcrystalline cellulose Filler Morepen Labs.Ltd.Parwanoo 
4. Colloidal Silicon Dioxide Glidant Morepen Labs.Ltd.Parwanoo 
5. Magnesium Stearate Lubricant Morepen Labs.Ltd.Parwanoo 
 
Table No. 2 EQUIPMENTS USED 
Sr.No. Equipments Manufacturer Capacity 
1. Fluid bed Dryer M/c S.B.Panchal & Co. 1.25 kg 
2. Planetary Mixer (PLM) M/s Gansons 5.0 Lit. 
3. Disintegration Tester M/s Electro Lab N.A 
4. Dissolution Tester M/s Electro Lab (TDT-80L) N.A 
5. Shifter M/s E.K.S Technique Min Capacity 1.0 Lit. 
6. LOD Tester Mettler Toledo(HB 43) N.A 
7. Hardness Tester M/s Tab Machine N.A 
8. Compression M/s (B 
Tooling) 
M/s Clit 10 Station 
9. Compression M/s (D 
Tooling) 
M/s Clit 16 Station 
10. Stirrer M/s Remi motors Type RQ-123, 38mm 
Propeller H.P-1/20 
11. Homogenizer M/s Remi motors Type RQ-127 
Propeller H.P-1/8 
12. Vernier calipers Mituto (Absolute digimatic) N.A 
13. Conventional coating 
pan, 12 & 16 inches 
M/c Betochem eng. 1.0 & 5.0 kg 
14. Weighing Balance 
(Model No. AB 204) 
M/c Mettler Max. 210 gm 
Min. 10 mg 
15. Weighing Balance 
(Model No. PB 302) 
M/c Mettler Max. 310 gm 
Min. 0.2 mg 
16. I.R moisture analyzer, 
model No. LJ-16 
M/c Mettler N.A 
17. Humidity Chamber, 2 
No. 
M/c Newtronics N.A 
18. Oven 45o C, 1 Number M/c Sintex N.A 
19. Oven 45o C, 2 Number M/c Narang N.A 
20. Photo stability 
Chamber, 1 Number 
M/c Newtronics N.A 
21. pH meter M/c Electronic India N.A 
22. U.V. 
Spectrophotometer 
M/c Parkin Elmer, 
Model-Lambda EZ 201 
N.A 
 
 
Preformulation Study 
Preformulation testing is the first step in the rational development of dosage form of a 
drug substance. It can be defined as an investigation of physical and chemical properties of a 
drug substance alone and when combined with excipients. The overall objective of 
preformulation testing is to generate information useful to the formulator in developing stable 
and bioavailability dosage forms that can be mass produced. 
Following the identification of a new chemical entity that is suitable for development, 
the formulator will be called upon to produce dosage form. Initially this may involve 
production of injectable from suitable for early efficiency and toxicity testing and 
subsequently there will be a need to develop the final dosage form which generally will not 
be injectable. The challenge for the formulator is to develop the initial and final dosage form 
to the highest quality in shortest time. This process is best achieved when certain 
physicochemical properties of the drug substance are investigated, understood and efficiency 
utilized, this is Preformulation. 
Preformulation Study can divide into two Subclasses: 
1. Compatibility Study 
2. Active Pharmaceutical Ingredient (API) Characterization. 
1. Compatibility Study: 
The Compatibility of drug and formulation components is an important prerequisite 
before formulation. It is therefore necessary to confirm that the drug does not react with the 
polymer and excipients under experimental condition and affect the shelf life of the product 
or any other unwanted effect on the formulation. 
2. Active Pharmaceutical Ingredient Characterization: 
¾ Organoleptic evaluation 
¾ Color 
¾ Taste 
¾ Odour 
 Need of Preformulation Studies: 
Scientific and regulatory justification of acquiring Preformulation data including the 
following: 
¾ Establishment of drug specification intended for toxicological evaluation and clinical 
supply preparation 
¾ Formulation of clinical supplies and establishment of their preliminary specification 
¾ providing scientific data to support dosage from development and evaluation of product 
efficiency, quality, stability, and Bioavailability  
¾ Evaluation of the stability of early development dosage forms. 
¾ Fulfillment of the requirement of the chemistry manufacturing control section of the 
investigation new drug (IND) and subsequent new drug application (NDA) or 
Abbreviated new drug application (AND). 
Preformulation Study Include Investigation of – 
1. Bulk Characterization 
¾ Crystalline and Polymorphism 
¾ Hygroscopicity 
¾ Fine Particle Characterization 
¾ Bulk Density 
¾ Powder Flow Properties  
2. Solubility Analysis 
¾ Ionization Constant- pKa 
¾ pH Solubility Profile  
¾ Common Ion Effect 
¾ Solubilization  
¾ Partition Coefficient  
¾ Dissolution 
3. Stability Analysis 
¾ Solid state stability of drug alone 
¾ Stability in presence of excipient (Compatibility Study) 
¾ Solution state stability (Stability in G.I fluid & Granulating solvents). 
4. Photo Stability Studies  
Analysis of Innovator Product: 
¾ Glycomet GP-1mg (USV) 
¾ Gluconorm-G1 (Lupin) 
A comparative analysis of innovator product and formulator product helps in calculation of 
the (f1) dissimilarity and (f2) similarity dissolution factor. Analysis of the innovator product 
was carried out for various physical parameter and In-vitro dissolution profile. 
Parameters:  
1. Shape 
2. Thickness Test   
3. Hardness Test 
4. Friability Test 
5. Weight Variation Test 
6. In-vitro Dissolution Study 
7. Drug Content Uniformity Test 
Table No. 3 Evaluation of Physical Property of Drug Excipients Mixtures:  
Sr.No Parameters 
Gluconorm-G1 (Lupin) 
Batch No. J090718 
Glycomet GP-1mg (USV) 
Batch No. 28000264 
1. Appearance 
One side break line light 
pink& other side white 
caplet 
One side break line light 
pink& other side off white 
caplet 
2. Thickness 7.08mm 6.90mm 
3. Diameter 18.5mm 17.03mm 
4. Hardness 4 kg/cm2 6 kg/cm2 
5. Friability 0.9 % 0.06 % 
6. Average weight 1100 mg 913 mg 
 
1. Angle of Repose : 
Flowability of mixture was determined by calculating angle of repose by fixed height 
method. A funnel with 1 mm diameter of stem was fixed at a height of 3.0 cm. over the 
platform. About 10 gm of sample was slowly passed along the wall of the funnel till the tip 
of the pile formed and touch the stem of the funnel. A rough circle was drawn around the pile 
base and radius of the powder cone was measured Angle of repose was calculated from the 
average radius using the following formula. 
Table No. 4 Flow Characteristics  
Angle of Repose Flow Characteristics 
< 25 Excellent 
25-30 Good 
30-40 Passable 
> 40 Very Poor 
 
r
htanθ 1−=  
Where: 
θ  = Angle of Repose 
h = Height of the Pile 
r = Average Radius of the Powder Cone. 
 
 
 
 
 
 
 
Table No. 5 Angle of Repose of Metformin Blend: 
Trials Height (cm) Radius (cm) Angle of Flow 
Repose (θ) Characteristics
Trial 1 3.0 5.5 28° 56' Good 
Trial 2 3.0 5.3 29° 50' Good 
Trial 3 3.0 5.4 29° 03' Good 
Trial 4 3.0 5.2 30° 34' Passable 
Trial 5 3.0 5.3 29° 50' Good 
 
Table No. 6 Angle of Repose of Glimepiride Blend 
Trials Height (cm) Radius (cm) Angle of Repose (θ) 
Flow 
Characteristics
Trial 1 3.0 5.8 27° 33' Good 
Trial 2 3.0 5.7 270 60' Good 
Trial 3 3.0 5.6 28° 14' Good 
Trial 4 3.0 5.7 27° 60' Good 
Trial 5 3.0 5.5 28° 59' Good 
 
2. Bulk Density:  
Bulk Density of all types of mixture was determined by pouring gently sample through a 
glass funnel into a 50 ml graduated cylinder. The volume occupied by the sample was 
recorded. Bulk Density was calculated. 
Sample by the Occupied Volume
Sample ofWeight (g/ml)Density Bulk =  
 
 
 
Table No. 7 Bulk Density of Glimepiride Blend: 
Trials Weight of Blend (gm) Volume of Blend (ml) Bulk Density (gm/ml) 
Trial 1 25.98 50 0.519 
Trial 2 26.12 50 0.522 
Trial 3 26.08 50 0.521 
Trial 4 26.53 50 0.530 
Trial 5 26.48 50 0.529 
 
Table No. 8 Bulk Density of Metformin Blend: 
Trials Weight of Blend (gm) Volume of Blend (ml) Bulk Density (gm/ml) 
Trial 1 23.25 50 0.465 
Trial 2 23.31 50 0.466 
Trial 3 23.48 50 0.469 
Trial 4 23.39 50 0.467 
Trial 5 23.41 50 0.468 
 
3. Tapped Density:  
Tapped Density was determined by using electrolab density tester, which consists of a 
graduated cylinder mounted on a mechanical tapping device. An accurately weighed sample 
of powder was carefully added to the cylinder with the aid of a funnel. Typically, the initial 
volume was noted, and the sample in then tapped (250, 500 & 750 Tapping) until no further 
reduction in volume is noted or the percentage of difference is not more than 2 %.A 
sufficient number of taps should be employed to assure reproducibility for the material in 
question. Volume was noted and Tapped Density is calculated using following formula. 
 
 
Table No. 9 Tapped Density of Glimepiride Blend: 
Trials Weight of Blend (gm) Volume of Blend (ml) Tapped Density (gm/ml) 
Trial 1 25.98 41 0.633 
Trial 2 26.12 41 0.637 
Trial 3 26.08 40 0.652 
Trial 4 26.53 41 0.647 
Trial 5 26.48 41 0.645 
   
Table No. 10 Tapped Density of Metformin Blend: 
Trials Weight of Blend (gm) Volume of Blend (ml) Tapped Density (gm/ml) 
Trial 1 23.25 40 0.581 
Sample by the Occupied Volume
Sample ofWeight (g/ml)Density  Tapped =
Trial 2 23.31 40 0.582 
Trial 3 23.48 41 0.572 
Trial 4 23.39 40 0.584 
Trial 5 23.41 40 0.585 
 
4. Compressibility %: 
It is also one of the sample methods to evaluate flow of a powder by comparing the Bulk 
Density and Tapped Density. A useful Empirical guide is given by the Carr’s 
Compressibility.  
100
Density Tapped
DensityBulk  -Density TappedIndex  sCarr' ×=  
 
 
 
 
Table No. 11 Compressibility Index of Glimepiride Blend 
Trials 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
 
Density  Tapped
DensityBulk  -Density  Tapped
 
Compressibility 
Index (%) 
Flow 
Character
Trial 1 0.519 0.633 0.1800 18.00 Fair 
Trial 2 0.522 0.637 0.1805 18.05 Fair 
Trial 3 0.521 0.652 0.2009 20.09 Passable 
Trial 4 0.530 0.647 0.1808 18.08 Fair 
Trial 5 0.529 0.645 0.1798 17.98 Fair 
 
Table No. 12 Compressibility Index of Metformin Blend 
 
Trials 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
 
Density  Tapped
DensityBulk  -Density  Tapped
 
Compressibility 
Index (%) 
Flow 
Character 
Trial 1 0.465 0.581 0.1996 19.96 Fair 
Trial 2 0.466 0.582 0.1993 19.93 Fair 
Trial 3 0.469 0.572 0.1800 18.00 Fair 
Trial 4 0.467 0.584 0.2003 20.03 Passable 
Trial 5 0.468 0.585 0.2000 20.00 Fair 
 
 
 
 
 
 
 
Table No. 13 Relationship of Flow Character with Compressibility Index (%) 
 
Compressibility Index (%) Flow Character 
≤ 10 Excellent 
11-15 Good 
16-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 Very poor 
>38 Very very poor 
 
Conclusion: The Flow Characteristic of both Metformin and Glimepiride Blend are fair. 
 
5. Hausner’s Ratio: 
It provide an indication of the degree of densification which could result from vibration of 
feed hopper 
DensityBulk 
Density Tapped  RatioHausner =  
Lower Hausner’s Ratio Î Better Flowability 
Higher Hausner’s Ratio Î Poor Flowability 
 
 
 
 
 
 
Table No. 14 Hausner’s Ratio of Glimepiride Blend 
Trials Bulk Density 
Tapped 
Density Hausner’s Ratio Flow Characteristics 
(gm/ml) (gm/ml) 
Trial 1 0.519 0.633 1.21 Fair 
Trial 2 0.522 0.637 1.22 Fair 
Trial 3 0.521 0.652 1.25 Fair 
Trial 4 0.530 0.647 1.22 Fair 
Trial 5 0.529 0.645 1.21 Fair 
 
Table No. 15 Hausner’s Ratio of Metformin Blend 
Trials 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
Hausner’s Ratio Flow Characteristics 
Trial 1 0.465 0.581 1.24 Fair 
Trial 2 0.466 0.582 1.24 Fair 
Trial 3 0.469 0.572 1.21 Fair 
Trial 4 0.467 0.584 1.25 Fair 
Trial 5 0.468 0.585 1.25 Fair 
 
Table No: 16 Relationship of Flow Character & Hauser’s Ratio 
Hausner’s Ratio Flow Character 
1.00-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.59 Very poor 
6. Sieve Analysis: 
The main aim of analysis is to determine the different size of drug particles present. A 
series of standard sieve were stacked one over the above so that sieve with larger pore size 
(Less sieve No.) occupy top position followed by a series of decreasing pore size (large sieve 
No.) towards the bottom. 
Procedure:  
The procedure involves the electromagnetic sieve shaking of the sample through the 
sieve of successively arranged sieve (sieve No 20, 30, 60, 80, 100 and receiver), and weight 
of the portion of the sample retained on each sieve and calculate percentage retained on each 
sieve. 
Results:  
50gm of both blend of Metformin and Glimepiride were analyzed separately on 
electromagnetic sieve shaking and weight of the portion of the sample retained on each sieve 
and calculate percentage retained on each sieve. 
Table No. 17 Results: 
API + 
Excipients 
Weight of 
material 
retained on 
sieve no 30 
# 
Weight of 
material 
retained on 
sieve no 40 
# 
Weight of 
material 
retained on 
sieve no 60 
# 
Weight of 
material 
retained on 
sieve no 80 
# 
Weight of 
material 
retained on 
sieve no 
above 80 # 
Metformin 
Blend 1.0 2.0 32.8 14.2 - 
Glimepiride 
Blend - 1.0 20.0 14.0 15.0 
 
 
 
 
 
 
Table No. 18 Sample Screen Analysis Data for Metformin Blend: 
U.S 
Standard 
Sieve Size 
Sieve 
opening 
(µm) 
Mean of 
class 
interval 
(µm) 
Granules 
weight on 
the smaller 
screen (gm) 
Percentage 
(%) 
Cumulative 
(%) weight 
> 12 1680 - - - - 
12-20 1680-840 1260 - - - 
20-40 840-420 630 1.0 1.0 50.0 
40-70 420-210 315 20.0 20.0 49.0 
70-140 210-105 157 29.0 29.0 29.0 
< 140 < 108 - - - - 
Grand 
Total   50.0 50.0 50.0 
 
Table No. 19 Sample Screen Analysis Data for Glimepiride Blend: 
U.S 
Standard 
Sieve Size 
Sieve 
opening 
(µm) 
Mean of 
class 
interval 
(µm) 
Granules 
weight on 
the smaller 
screen (gm) 
Percentage 
(%) 
Cumulative 
(%) weight 
> 12 1680 - - - - 
12-20 1680-840 1260 - - - 
20-40 840-420 630 3.0 3.0 50.0 
40-70 420-210 315 32.8 33.0 47.0 
70-140 210-105 157 14.1 14.0 14.0 
< 140 < 108 - - - - 
Grand 
Total   49.9 50.0 50.0 
 
7. Loss on Drying:  
Loss of drying is the loss of weight expressed as percentage W/W resulting from 
water and volatile matter of any kind that can be driven off under specified conditions the test 
is carried on a well mixed sample of the substance. If the substance is the form of large 
crystals, reduce the size by rapid crushing to a powder.   
Method: 0.5 – 1.5 g of sample of blends was accurately weighed and the powder was kept in 
a Mettler Toledo Apparatus for 5 min. at 105°C and the moisture content was calculated.  
Table No. 20 Loss on Drying of Metformin Blend: 
Trials Sample Initial weight (gm) Final weight (gm) LOD (%) 
1 0.534 0.517 3.18 
2 1.046 1.013 3.15 Trial 1 
3 1.522 1.475 3.08 
1 0.508 0.491 3.34 
2 1.052 1.017 3.32 Trial 2 
3 1.510 1.020 3.24 
1 0.512 0.496 3.12 
2 1.008 0.976 3.17 Trial 3 
3 1.534 1.485 3.19 
1 0.521 0.507 2.68 
2 1.032 1.005 2.61 Trial 4 
3 1.520 1.480 2.63 
1 0.520 0.508 2.30 
2 1.021 0.998 2.26 Trial 5 
3 1.560 1.525 2.24 
 
 
 
Table No. 21 Loss on Drying of Glimepiride Blend: 
 
Trials Sample Initial weight (gm) Final weight (gm) LOD (%) 
Trial 1 1 0.502 0.485 3.38 
2 1.064 1.029 3.28  
3 1.518 1.468 3.29 
1 0.512 0.498 2.73 
2 1.036 1.010 2.50 
Trial 2 
3 1.517 1.480 2.43 
1 0.506 0.495 2.17 
2 1.024 1.002 2.14 
Trial 3 
3 1.528 1.495 2.15 
1 0.520 0.492 5.38 
2 1.043 0.987 5.36 
Trial 4 
3 1.532 1.450 5.35 
1 0.511 0.483 5.47 
2 1.002 0.947 5.39 
Trial 5 
3 1.520 1.438 5.39 
 
8. Drug Excipients Compatibility (Stability in Presence of Excipients):  
 A drug or active principal is most often delivered to patient along with other chemical 
substance within a pharmaceutical formulation, which should comply with strict 
specification, often prescribed by law. In order to be approved, formulation should warrant 
well defined level of stability, safety and efficacy.  The desired level of stability is often 
difficult to achieve   because the active principal may interact with the other substance of the 
formulation, the so called excipients which do not have a specified pharmaceutical activity. 
 Some time, this interaction is fundamental for a proper functioning of the drug 
delivery system (e.g. to speed up dissolution, or controlling release). In most cases of 
mechanical drug excipients mixture in the solid state, however we would like to predict 
possible negative effect of the inter reaction, faster degradation rate chemical changes etc. 
Most often, the negative effect of the drug excipients interaction in the solid state medicated 
by water and enhanced by an increased temperature in fact vapor released by the excipients 
may be absorbed /adsorbed by the drug or water bonded to the excipients may promote a 
reaction at the excipients drug inter phase in the first case (vapor mediated mechanism) the 
effect should be the more important at higher the concentration of the Excipients. In the 
second case, we often here partial salvation in the interphase are and even traces of water 
may place a major role in degradation of water- soluble through an increased mobility of 
drug –excipients which enhance their reactivity. 
 Owing to the length and complexity of the approval process, it is of paramount 
importance to address the drug-excipients. Compatibility issue from the early stage of 
Preformulation. The standard “Fast stability test” involve storing binary drug-excipients 
mixture under extreme temperature and humidity condition and periodically determining the 
drug concentration possible pitfall of this test is that concentration dependent effect are 
usually not identified, while some of the reaction observed at high temperature /humidity 
may not occurs in normal stage storage. 
Need of Drug Excipients Compatibility Study: 
1. To provide the information to the formulator which will help to select the Excipients 
for formulation of dosage form 
2. To check whether the stability is ascertain during the toxicological study during the 
toxicological study. 
3. To check the shelf life of drug in presence of excipients. 
4. To check the loss of pharmaceutical elegance (fading of colored solution and tablets). 
5. To check the bioavailability in presence of different excipients. 
6. To check the loss of active ingredient. 
 
 In this study the excipients were selected which are generally used in tablets 
formulation. Ratio of drug Vs. excipients is taken as per their concentration in prototype 
development formula. To maximize possible physicochemical interaction, drug and 
excipients were mixed together into two ways as follow: 
(1) Drug was mixed with Excipients in dry form kept in a colorless and transparent vial 
with rubber plug and aluminum seal. 
(2) Drug was mixed with excipients in dry form then granulated with and IPA then dried, 
these granules are kept in colorless and transparent vial rubber plug and aluminum 
seal.  
All the samples as described below were kept at:  
 25° C, 
 25° C / 60 % RH 
 40° C 
 40° C/ 75 % RH 
Incubation Conditions : 25° C,  25° C/60 % RH, 40° C, 40° C/ 75 % RH 
Intervals: 2 weeks, 4 weeks, 6 weeks 
Quantity: Approx 100 mg/vial 
Packing Material: USP Type-I clear and temperature glass vials of capacity 10ml, gray  
           Butyl rubber plug and aluminum seals 
Table No. 22 Material Used in Order to Perform Preformulation Study 
Material Used in Order to Perform Preformulation Study: 
According to the functional category these excipients are mixed in different ratio with drug, 
these mixtures are kept in 25° C, 25° C/60 % RH, 40° C, 40° C/ 75 % RH. In a Type-I clear 
and transparent Glass vials of capacity 10ml.grey butyl rubber plugs and aluminum seals. 
The excipients are mixed with Metformin and Glimepiride and sample are withdrawn at the 
interval of 2 weeks, 4 weeks, 6 weeks and the sample are withdrawn and given to analytical 
development department for analysis of following parameters. 
¾ Moisture contents 
¾ Related Substance  
¾ Assay 
¾ Organoleptic Properties  
Table No. 23 Part – I Individual Excipients in Dry Form: 
Sr.No. Name Category Suppliers of Material 
1. Metformin API Morepen Labs. Ltd. Parwanoo. 
2. Glimepiride API Morepen Labs. Ltd. Parwanoo. 
3. Methocel Polymer Morepen Labs. Ltd. Parwanoo. 
4. MCC Filler Morepen Labs. Ltd. Parwanoo. 
5. Colloidal Silicon Dioxide Glident Morepen Labs. Ltd. Parwanoo. 
6. Magnesium Stearate Lubricant Morepen Labs. Ltd. Parwanoo. 
7. Color Colorant Morepen Labs. Ltd. Parwanoo. 
8. Starch 1500 Filler Morepen Labs. Ltd. Parwanoo. 
 Sr.No. Name of the Excipients 
1. Metformin (Ratio: 100%) 
2. Glimepiride (Ratio: 100%) 
3. Methocel (Ratio: 100%) 
4. Microcrystalline Cellulose (Ratio: 100%) 
5. Colloidal Silicon Dioxide (Ratio: 100%) 
6. Magnesium Stearate (Ratio: 100%) 
7. Color (Ratio: 100%) 
 
 
 
 
Table No. 24 Part – II Metformin: Excipients in Dry Form: 
 
Sr.No. Name of the Excipients 
1. Glimepiride (X=20, Ratio- 10 : 10) 
2. Methocel (X= 5, Ratio- 10 : 2.5 ) 
3. Microcrystalline Cellulose(MCC-102) (X=30, Ratio-10 : 10 ) 
4. Colloidal Silicon Dioxide (X= 1,Ratio- 10 : 0.5 ) 
5. Magnesium  Stearate (X= 1,Ratio- 10 : 0.5 ) 
 
Table No. 25 Part – III Glimepiride: Excipients in Dry Form: 
 
Sr.No. Name of the Excipients 
1. Metformin (X=20, Ratio- 10 : 10) 
2. Starch 1500 (X= 5, Ratio- 10 : 2.5 ) 
3. Microcrystalline Cellulose (MCC-102) (X=30, Ratio-10 : 10 ) 
4. Colloidal Silicon Dioxide (X= 1,Ratio- 10 : 0.5 ) 
5. Magnesium  Stearate (X= 1,Ratio- 10 : 0.5 ) 
6. Color (X= 1,Ratio- 10 : 0.5 ) 
 
 
 
Table No.26 Part – IV Metformin: Excipients in Wet Form Dried at 40° C, (LOD: 1-
3%): 
Sr.No. Name of the Excipients 
1. Glimeperide (X=20, Ratio- 10 : 10) 
2. Methocel (X= 5, Ratio- 10 : 2.5 ) 
3. Microcrystalline Cellulose (MCC-102) (X=30, Ratio-10 : 10 ) 
4. Colloidal Silicon Dioxide (X= 1,Ratio- 10 : 0.5 ) 
5. Magnesium  Stearate (X= 1,Ratio- 10 : 0.5 ) 
 
Table No. 27 Part – V Glimepiride: Excipients in Wet Form Dried at 40° C, (LOD: 1-
3%): 
  
 
Results:   
Sr.No. Name of the Excipients 
1. Metformin (X=20, Ratio- 10 : 10) 
2. Starch 1500 (X= 5, Ratio- 10 : 2.5 ) 
3. Microcrystalline Cellulose (MCC-102) (X=30, Ratio-10 : 10 ) 
4. Colloidal Silicon Dioxide (X= 1,Ratio- 10 : 0.5 ) 
5. Magnesium  Stearate (X= 1,Ratio- 10 : 0.5 ) 
6. Color (X= 1,Ratio- 10 : 0.5 ) 
Table No. 28 Drug- Excipients Compatibility Study: 
Conclusion: Metformin HCl is compatible with the all excipients and not shown any 
impurities   
Condition 
40° C/75% RH 25° C/60% RH 
Sr. 
No 
Drug  
+  
Excipients 
Drug  
Excipients 
Ratio 
Parameters Initial 
Value of 
Parameters 2week
s 
4week
s 
2week
s 
4week
s 
Moisture 
content 
5.60 5.18 4.87 4.72 5.21 1. Metformin  
+  
Methocel 
1: 2.5 
Assay (%) 101.21 100.0 99.78 100 101.68 
Moisture 
content 
4.23 4.23 4.12 4.02 4.31 2. Metformin 
+ 
Microcrystalline 
Cellulose 
1:2 
Assay 99.95 99.76 99.80 99.90 99.68 
Moisture 
content 
3.68 3.62 3.42 3.12 3.60 3. Metformin  
+ 
 Colloidal 
Silicon Dioxide 
1:0.1 
Assay 100.25 99.85 100.02 100 98.80 
Moisture 
content 
2.87 2.52 2.32 2.78 2.70 4. Metformin  
+  
Magnesium  
Stearate 
1:0.1 
Assay 102.08 98.74 100.21 100.00 99.92 
Table No. 29 Drug- Excipients Compatibility Study: 
Condition 
40° C/75% RH 25° C/60% RH 
Sr.No Drug  
+  
Excipients 
Drug  
Excipients 
Ratio 
Parameters Initial 
Value of 
Parameters 2weeks 4weeks 2weeks 4weeks
Moisture 
content 
2.36 1.87 2.10 2.28 2.30 1. Glimepiride  
+  
Starch 1500 
1:0.5 
Assay 102.65 100.02 100.0 99.85 100 
Moisture 
content 
3.56 2.36 2.20 3.21 3.48 2. Glimepiride 
+ 
Microcrystalline 
Cellulose 
1:2 
Assay 99.78 98.56 99.28 99.66 99.25 
Moisture 
content 
2.35 1.89 2.10 2.27 2.18 3. Glimepiride 
 + 
Colloidal 
Silicon Dioxide 
1:0.1 
Assay 101.35 99.02 100 101.00 100 
Moisture 
content 
2.25 1.95 2.00 2.17 2.19 4. Glimepiride 
 + 
 Magnesium  
Stearate 
1:0.1 
Assay 102.48 100.02 101.2 101.67 100 
Conclusion: Glimepiride stable with all excipients, No affect of moisture on assay.
ORGANOLEPTIC PROPERTIES OF DRUG IN PRESENCE OF EXCIPIENTS AT 
DIFFERENT INTERVAL 
Table No. 30 Change in Color at Different Time Interval in Presence of Excipients: 
 
Change in Colors Sr.No. Name of the Material Initial 
Color 2 weeks 4 weeks 6 weeks 
1. Metformin + Methocel White -- -- -- 
2. Methocel White -- -- -- 
3. Metformin + Microcrystalline 
Cellulose 
White -- -- -- 
4. Microcrystalline Cellulose White -- -- -- 
5. Metformin + Colloidal Silicon 
Dioxide  
White -- -- -- 
6. Colloidal Silicon Dioxide White -- -- -- 
7. Metformin + Magnesium  
Stearate 
White -- Brown Brown 
8. Magnesium  Stearate White -- -- -- 
9. Metformin+ Starch 1500 White -- -- -- 
10. Starch 1500 White -- -- -- 
Conclusion:  
 Metformin is stable with most of the excipients in case of magnesium Stearate 
,causing the discoloration of the product, the change in color was observed that will not 
affect the stability of the product so use of magnesium Stearate as lubricant in less quantity to 
avoid discoloration. 
 
Table No. 31 Change in Color at Different Time Interval in Presence of Excipients: 
 
Change in Colors Sr.No. Name of the Material Initial 
Color 2 weeks 4 weeks 6 weeks 
1. Glimepiride + Starch 1500 White -- -- -- 
2. Starch 1500 White -- -- -- 
3. Glimepiride + White -- -- -- 
Microcrystalline Cellulose 
4. Microcrystalline Cellulose White -- -- -- 
5. Glimepiride + Colloidal 
Silicon Dioxide  
White -- -- -- 
6. Colloidal Silicon Dioxide White -- -- -- 
7. Glimepiride + Magnesium  
Stearate 
White -- -- -- 
8. Magnesium  Stearate White -- -- -- 
9. Glimepiride + Color Red -- -- -- 
 
Conclusion: Glimepiride is stable with all the excipients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No. 32 Formulation of Metformin HCl Layer: 
 
 
  
Method of 
Formulation 
Direct 
compression
Direct 
compression 
Direct 
compression 
Direct 
compression 
Direct 
compression 
Trial No. 
Sr. 
No 
Ingredients 
Trial-1 Trial-2 Trial-3 Trial-4 Trial-5 
1 Metformin HCl 500 500 500 500 500 
2 Methocel K100 M 288 288 315 300 297.50 
3 Microcrystalline 
cellulose 
50.75 50.75 23.75 40.25 44.00 
4 Colloidal Silicon 
Dioxide 
5.00 5.00 5.0 4.25 4.25 
5 Magnesium 
Stearate 
5.00 5.00 5.0 4.25 4.25 
Total weight (mg) 848.75 848.75 848.75 848.75 850 
Table No. 33 Formulation of Glimepiride Layer: 
 
 
Methodology of Metformin Layer Preparation: 
 
Direct compression: 
 
¾ Weigh accurate quantity of Metformin layer based on its potency 
Method of Formulation 
Wet 
granulation 
Wet 
granulation 
Wet 
granulation
Direct 
compression 
Direct 
compression 
Trial No. 
Sr. 
No 
Ingredients 
Trial - 1 Trial - 2 Trial - 3 Trial - 4 Trial - 5 
1. Glimepiride 1.0 1.0 1.0 1.0 1.0 
2. Lactose monohydrate 80.0 65 75 -- -- 
3. Microcrystalline 
cellulose Plain 
115.9 131.85 120 -- -- 
4. Sodium starch 
Glycolate 
28 25 30 -- -- 
5. Color 0.060 0.1 0.2 -- -- 
6. 
Poly vinayl pyrolidone 
K-30 
18.0 20.0 180 -- -- 
7. 
Sodium starch 
Glycolate 
5.0 5.0 5.3 -- -- 
8. Color (Iron red oxide) 0.04 (Supra) 0.05 (Supra) 
0.05 
(Supra) 
0.10 ( Lake) 0.15 (Lake) 
9 Starch 1500 -- -- -- 60.0 45 
10 Microcrystalline 
cellulose Rank 
-- -- -- 186..9 201.85 
11 Colloidal Silicon 
Dioxide 
-- -- -- 1.0 1.0 
12 Magnesium Stearate 2.0 2.0 0.5 1.0 1.0 
Total Weight (mg) 250 250 250 250 250 
¾ Weigh and add Methocel, Microcrystalline Cellulose, and Colloidal Silicon Dioxide 
through sieve size 40 and Magnesium Stearate through sieve size 60. 
¾ Mix all ingredients well in planetary mixture for 15 min at impeller speed 100 rpm. 
¾ After mixing blend the same in Octagonal Blender for 20 min. after that Magnesium 
Stearate which was sieved from sieve size 60 was added and blend all material for 5 
min. 
¾ Final blend was compressed by 18.5 X 9 mm caplet one side break line, other side 
plane punches in Cadmech Compression Machine. 
¾ Same method was applied for Trial 1, 2, 3 & 4 
¾ In Trial 5 method was adapted which was same as direct compression the difference 
lies that the release rate of Metformin is sustained. 
¾ This blend was compressed by adding adequate quantity of lubricant mentioned 
above in Cadmech Compression Machine. 
Methodology for Glimepiride Layer Preparation: 
Wet Granulation: 
 
¾ Weigh accurate quantity of Glimepiride based on its potency. 
¾ Weigh and add Methocel, Microcrystalline Cellulose, and Colloidal Silicon Dioxide 
through sieve size 40 and Magnesium Stearate through sieve size 60. 
¾ Mix all ingredients well in planetary mixture for 15 min at impeller speed 100 rpm. 
¾ After mixing blend the same in Octagonal Blender for 20 min, after that Magnesium 
Stearate which sieved from sieve size 60 was added and blend all material for 5 min. 
¾ Final blend was compressed by 18.5 X 9 mm caplet one side break line, other side 
plane punches in Cadmech compression machine. 
¾ Same method was applied for Trial 1, 2 & 3. 
¾ In wet granulation the results are not satisfactory so the direct compression method 
applied in next batches  
Direct compression 
¾ In Trial 4 method was adapted which is direct compression the difference lies that the 
release rate of Metformin is not Satisfactory. 
¾ In Trial 5 method was adapted which is direct compression the difference lies that the 
release rate of Metformin and other parameters is Satisfactory. 
¾ This blend was compressed by adding adequate quantity of lubricant mentioned 
above in Cadmech Compression Machine. 
 
Methodology: 
 
In this process the granules of each blend were filled separately in the hopper in 
Double rotatory compression machine. Machines were engineered to compress each layer 
separately before the deposition of the next granulation, with a final compression for the 
complete tablet. Since in this machine, the excess granulation from each feed frame could not 
be permitted to circulate around the turret and commingle, wipe off blades covering the 
entire face of the die table has been installed. The excess was thus directed into pots at the 
side of the press and manually returned to appropriate hopper. Suction tubes were needed to 
remove any fine dust that escapes under the scraper blades. The arrangement described above 
is installed on the presses, prevent one granulation from contaminating the other. 
Table no. 34 Optimization formula for the development of scale up Batches 
Sr.No Ingredients Specification mg/tab 
1. Metformin HCl I.P 500 
2. Methocel K100 M I.P 297.50 
3. Microcrystalline cellulose I.P 44.0 
4. Colloidal Silicon Dioxide I.P 4.25 
5. Magnesium Stearate I.P 4.25 
6. Glimepiride I.P 1 
7. Colloidal Silicon Dioxide I.P 1.0 
8. Microcrystalline cellulose I.P 236.85 
9. Starch 1500 I.P 60 
10. Color (Iron red oxide) I.P 0.15 
11. Magnesium Stearate I.P 1.0 
 
Evaluation  
Post Compression Parameters: 
1. Shape of Tablets:  
Randomly picked tablets from each formulation were examined for the shape 
of the tablets 
2. Weight Variation Test:  
Twenty tablets were weighed and the average weight was calculated. The 
individual weight was compared with the average weight. The tablets pass the test if 
not more than two tablets are outside the percentage limit and if no tablets differs by 
more than two tablets the percentage limit. The following percentage deviation in 
weight variation is allowed according to USP. 
 
Table No.:  35 Limits of weight variation according to tablets weight 
 
In all the formulation the tablets weight is more than 324 mg or more, hence 5% 
maximum difference allowed. 
 
 
 
 
 
Table No. 36 Weight Variation Test  
Sr. No Average weight of tablet Percentage weight variation 
1. 130 mg or less 10 % 
2. More than 130 mg and less than 324 mg 7.5 % 
3. 324 mg or more 5 %\ 
Sr.No Trial-1 Trial-2 Trial-3 Trial-4 Trial-5 
1. 1102 1088 1109 1110 1099 
2. 1125 1109 1094 1080 1089 
3. 1086 1121 1102 1085 1124 
4. 1094 1102 1099 1100 1088 
5. 1110 1089 1089 1124 1109 
6. 1091 1125 1110 1089 1105 
7. 1089 1085 1080 1125 1110 
8. 1121 1127 1085 1085 1080 
9. 1109 1086 1100 1127 1085 
10. 1085 1086 1124 1086 1100 
11. 1102 1109 1088 1082 1124 
12. 1086 1094 1109 1109 1089 
13. 1124 1102 1121 1094 1125 
14. 1100 1099 1102 1102 1085 
15. 1080 1089 1089 1099 1127 
16. 1099 1110 1125 1089 1086 
17. 1109 1080 1085 1124 1082 
18. 1127 1085 1127 1088 1100 
19. 1089 1100 1086 1109 1125 
20. 1088 1124 1082 1105 1085 
Average 
weight 1100.8 1100.5 1100.3 1100.6 1100.85 
 
3. Uniformity of Thickness:  
Ten tablets were picked from formulation randomly and thickness was measured 
individually using Vernier-caliper. It is expressed in millimeter and average was calculated. 
Table No. 37 Uniformity of Thickness 
 
Sr.No Trial -1 Trial -2 Trial -3 Trial -4 Trial -5 
1. 6.41 6.44 6.4 6.48 6.48 
2. 6.38 6.48 6.41 6.41 6.47 
3. 6.39 6.41 6.43 6.48 6.45 
4. 6.31 6.45 6.47 6.41 6.42 
5. 6.33 6.43 6.42 6.4 6.44 
Average 6.36 6.44 6.42 6.43 6.45 
 
4. Hardness Test:  
Hardness indicates the ability of a tablet to withstand mechanical shocks while 
handling. The hardness of the tablets was determined using Monsanto hardness tester. It 
was expressed in kg/cm2. Ten tablets were randomly picked and hardness of the same 
tablets from each formulation was determined. The average value was also calculated. 
 
Table No. 38 Hardness Test 
 
Sr. No. Trial-1 Trial-2 Trial-3 Trial-4 Trial-5 
1. 8.0 6.0 5.0 7.0 6.0 
2. 8.0 7.0 6.0 6.0 6.0 
3. 7.0 5.5 7.0 6.0 5.0 
4. 8.0 6.0 6.0 5.0 7.0 
5. 7.0 6.0 6.0 6.0 6.0 
Average 8 6 6 6 6 
 
 
 
 
5. Friability Test:  
The friability of tablets was determined using Roche Friabilator. It is expressed in 
percentage (%). Twenty tablets were initially weighed and transferred into Friabilator 
which was operated at 25 rpm for 4 minutes. The tablets were weighed again and 
calculate the friability by this formula:  
100
 weightInitial
 weightFinal - weightInitial Friability % ×=  
% Friability of tablets less than 1% is considered acceptable.  
Table No. 39 Friability Test 
Sr. No Trial-1 Trial-2 Trial-3 Trial-4 Trial-5 
1. 0.75 0.37 0.52 0.16 0.11 
2. 0.68 0.31 0.58 0.11 0.13 
3. 0.71 0.38 0.51 0.17 0.09 
4. 0.78 0.33 0.55 0.14 0.12 
5. 0.74 0.35 0.52 0.18 0.14 
Average 0.732 0.348 0.536 0.152 0.118 
 
Results: 
Table No. 40 The Post Compression Parameter are evaluated. 
Sr. No. Parameters Specification Results 
1. Appearance 
One side break line   
& other side plain 
caplet 
One side break line   & 
other side plain caplet 
2. Thickness 6.5 mm 6.45mm 
3. Diameter 18.50 mm 18.5 mm 
4. Hardness NLT 2.0 kg/cm2 6.0 kg/cm2 
5. Friability NMT 1% 0.118 % 
6. Average Weight 1100 mg 1100.85mg 
Content Uniformity of Glycomet GP-1mg (USV): 
Standard Preparation of Glimepiride:  
Weigh and accurately transferred 10.7 mg of Glimepiride working standard into a 50 ml 
volumetric flask and make up the volume with mobile phase up to 50 ml, from the above 
stock solution, take 5ml in 100 ml volumetric flask and make up the volume with the mobile 
phase. 
Sample Preparation of Glimepiride:  
Take 1 intact Bi-layer tablet of Glimepiride and Metformin in 100 ml volumetric flask, 
dissolve in 25 ml of mobile phase make up the volume with mobile phase  
Fig No. 5 Content Uniformity Chromatogram of Glycomet GP-1mg (USV) 
Table No 41 Content Uniformity Peak Summary with Statistics of Glycomet GP-1mg 
(USV)  
 Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 3:44:16 PM11/20/2009
1
2
3
4
5
6
7
8
9
10
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#USV28000264   ...C.U.-1
#USV28000264    ...C.U.-2
#USV28000264   ...C.U.-3
#USV28000264    ...C.U.-4
#USV28000264  ...C.U.-5
#USV28000264    ...C.U.-6
#USV28000264   ...C.U.-7
#USV28000264   ...C.U.-8
#USV28000264   ...C.U.-9
#USV28000264    ...C.U.-10
5
6
7
8
9
10
11
12
13
14
1
1
1
1
1
1
1
1
1
1
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
3.997
3.998
3.988
3.984
3.983
3.979
3.984
3.978
3.978
3.979
3.985
0.007
0.19
181420
195320
181196
196132
180921
178195
179243
176079
178592
181588
182868.5
6997.2
3.8
0.33
0.35
0.32
0.35
0.32
0.31
0.31
0.31
0.31
0.32
16274
18312
15658
17906
15356
15180
15261
14684
14960
15031
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
3
4
5
6
7
8
9
10
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#USV28000264   ...C.U.-1
#USV28000264    ...C.U.-2
#USV28000264   ...C.U.-3
#USV28000264    ...C.U.-4
#USV28000264  ...C.U.-5
#USV28000264    ...C.U.-6
#USV28000264   ...C.U.-7
#USV28000264   ...C.U.-8
#USV28000264   ...C.U.-9
#USV28000264    ...C.U.-10
5
6
7
8
9
10
11
12
13
14
1
1
1
1
1
1
1
1
1
1
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
1.444
1.442
1.438
1.429
1.437
1.429
1.429
1.440
1.441
1.442
1.437
0.006
0.41
54508109
55431259
55957589
56224695
56519832
56808874
57297338
56775180
57149601
57208499
56388097.7
887308.2
1.6
99.67
99.65
99.68
99.65
99.68
99.69
99.69
99.69
99.69
99.68
2857294
2852346
2849535
2874829
2848692
2879182
2892474
2849052
2848978
2850203
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Calculation: 
 
Assay of Glycomet GP-1mg (USV) 
Standard preparation of Glimepiride: Weigh and accurately transferred 10.5 mg of 
Glimepiride and 490.6 mg of Metformin working standard into a 100 ml volumetric flask and 
make up the volume with mobile phase up to 100 ml 
Sample preparation of Glimepiride: Weigh accurately 20 tablets each containing 500mg 
Metformin and 1 mg Glimepiride crush them in to fine powder. Weight equivalent to 
Metformin and Glimepiride, transfer the powder to 100 ml volumetric flask. Filter the 
solution through 0.45 µ GFC filter paper  
Procedure: Assay was carried out in HPLC (water system) including pump, photodiode 
array detector. Separately injected 10μl of the standard and the sample preparation in to the 
liquid chromatography and record the area for the major peak. 
The chromatographic conditions described under may be used. 
System  :  Waters 2695 
Column  :  A Stainless steel column C18 (250 X 4.6 mm), 5 µm 
Flow Rate  :  1.5ml/min 
Mobile Phase  :  Acetonitrile (600) + Methanol (400)  
Wavelength  :  228 nm 
Injection Volume :   10 µl 
Run Time  :  8 min 
Column Temperature :  48°C 
Fig No. 6 Blank Chromatogram of Glycomet GP-1mg (USV) 
Sample Report 
Project Name:   PDA2009IInd Reported by User:   System 
Report Method:  Result Set Report Printed 1:56:40 PM11/5/2009
S A M P L E      I N F O R M A T I O N
Sample Name: Acquired By:  System  Blank Glimeperide+Metformine 
Sample Type: Date Acquired: Unknown   11/3/2009 11:03:39 AM  
Vial: Acq. Method Set: 1   MOREPEN 
Injection #: Date Processed: 1   11/5/2009 1:49:51 PM  
Injection Volume: Processing Method: 10.00 ul  GLIMIPEN MF 
Run Time: Channel Name: 8.0 Minutes  2487Channel 1 
Sample Set Name: Proc. Chnl. Descr.: GLIMIPEN MF   228 
AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 
Fig No. 7 Standard Chromatogram of Glycomet GP-1mg (USV) 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:23:55 PM11/3/2009
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 1; Date Acquired 11/3/2009 11:12:26 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 2; Date Acquired 11/3/2009 11:21:12 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 3; Date Acquired 11/3/2009 11:29:57 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 4; Date Acquired 11/3/2009 11:38:56 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 5; Date Acquired 11/3/2009 11:47:42 AM
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Table No. 42 Standard Peak Summary with Statistics Glycomet GP-1mg (USV) 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 1:58:48 PM11/5/2009
1
2
3
4
5
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
2
2
2
2
2
1
2
4
5
3
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
4.022
4.009
3.993
3.989
4.000
4.003
0.013
0.33
193503
192717
193277
192085
194133
193143.0
779.3
0.4
0.35
0.35
0.35
0.35
0.35
20555
20565
21016
21079
21013
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
3
4
5
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
2
2
2
2
2
1
5
4
3
2
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
1.408
1.411
1.410
1.396
1.409
1.407
0.006
0.43
55682737
55332874
55344703
55177401
55201356
55347814.0
201802.4
0.4
99.65
99.65
99.65
99.65
99.65
2843879
2850927
2846095
2904167
2836561
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Fig.No. 8 Assay Chromatogram of Glycomet GP-1mg (USV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 3:42:03 PM11/20/2009
Sample Name: #USV28000264    ...Assay ;   Vial: 4; Injection: 1; Date Acquired 11/3/2009 12:14:19 PM
Sample Name: #USV28000264    ...Assay ;   Vial: 4; Injection: 2; Date Acquired 11/3/2009 12:23:05 PM
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Table No. 43 Assay Peak Summary with Statistics of Glycomet GP-1mg (USV) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calculation: 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 3:42:03 PM11/20/2009
1
2
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#USV28000264    ...Assay
#USV28000264    ...Assay
4
4
1
2
Glimepiride
Glimepiride
3.981
3.983
3.982
0.001
0.02
181374
179675
180524.3
1201.3
0.7
0.32
0.31
16854
15719
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#USV28000264    ...Assay
#USV28000264    ...Assay
4
4
1
2
Metformine HCl
Metformine HCl
1.426
1.428
1.427
0.002
0.13
57059385
57055520
57057452.8
2733.2
0.0
99.68
99.69
2839368
2846095
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Signature..............
Content Uniformity of Gluconorm-G1 (Lupin) 
Standard preparation of Glimepiride:  
Weigh and accurately transferred 10.7 mg of Glimepiride working standard into a 50 ml 
volumetric flask and make up the volume with mobile phase up to 50 ml, from the above 
stock solution take 5ml in 100 ml volumetric flask and make up the volume with the mobile 
phase. 
Sample preparation of Glimepiride:  
Take 1 intact Bi-layer tablet of Glimepiride and Metformin in 100 ml volumetric flask, 
dissolve in 25 ml of mobile phase make up the volume with mobile phase  
Fig No. 9 Content Uniformity Chromatogram of Gluconorm-G1 (Lupin) 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:01:53 PM11/5/2009
Sample Name: #J090718....C.U....1;   Vial: 5; Injection: 1
Sample Name: #J090718....C.U....2;   Vial: 6; Injection: 1
Sample Name: #J090718....C.U....3;   Vial: 7; Injection: 1
Sample Name: #J090718....C.U....4;   Vial: 8; Injection: 1
Sample Name: #J090718....C.U....5;   Vial: 9; Injection: 1
Sample Name: #J090718....C.U....6;   Vial: 10; Injection: 1
Sample Name: #J090718....C.U....7;   Vial: 11; Injection: 1
Sample Name: #J090718....C.U....8;   Vial: 12; Injection: 1
Sample Name: #J090718....C.U....9;   Vial: 13; Injection: 1
Sample Name: #J090718....C.U....10;   Vial: 14; Injection: 1
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Table No 44 Content Uniformity Peak Summary with Statistics of Gluconorm-G1 
(Lupin) Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:01:53 PM11/5/2009
1
2
3
4
5
6
7
8
9
10
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#J090718....C.U....1
#J090718....C.U....2
#J090718....C.U....3
#J090718....C.U....4
#J090718....C.U....5
#J090718....C.U....6
#J090718....C.U....7
#J090718....C.U....8
#J090718....C.U....9
#J090718....C.U....10
5
6
7
8
9
10
11
12
13
14
1
1
1
1
1
1
1
1
1
1
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
3.997
3.998
3.988
3.984
3.983
3.979
3.984
3.978
3.978
3.979
3.985
0.007
0.19
174594
197983
181751
198743
176271
178195
179608
173951
179503
179180
181977.9
8960.8
4.9
0.32
0.36
0.34
0.36
0.32
0.32
0.32
0.31
0.32
0.32
16085
18375
15670
17984
15246
15180
15292
14754
15059
14976
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
3
4
5
6
7
8
9
10
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#J090718....C.U....1
#J090718....C.U....2
#J090718....C.U....3
#J090718....C.U....4
#J090718....C.U....5
#J090718....C.U....6
#J090718....C.U....7
#J090718....C.U....8
#J090718....C.U....9
#J090718....C.U....10
5
6
7
8
9
10
11
12
13
14
1
1
1
1
1
1
1
1
1
1
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
1.444
1.442
1.429
1.429
1.429
1.429
1.429
1.429
1.429
1.429
1.432
0.006
0.41
53874193
55431259
53501847
54362824
55047877
55265451
55462597
55702627
55947064
55440279
55003601.8
814791.5
1.5
99.68
99.64
99.66
99.64
99.68
99.68
99.68
99.69
99.68
99.68
2854271
2852346
2868746
2865774
2873418
2872275
2884211
2891853
2894245
2895357
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Calculation :
Assay of Gluconorm-G1 (Lupin): 
Standard preparation of Glimepiride:  
Weighed and accurately transferred 10.6 mg of Glimepiride and 490.5 mg of 
Metformin working standard into a 100 ml volumetric flask and make up the volume with 
mobile phase up to 100 ml 
Sample preparation of Glimepiride:  
Weighed accurately 20 tablets each containing 500mg Metformin and 1 mg 
Glimepiride crush them in to fine powder. Weight equivalent to Metformin and Glimepiride, 
transfer the powder to 100 ml volumetric flask. Filter the solution through 0.45 µ GFC filter 
paper  
Procedure: Assay was carried out in HPLC (water system) including pump, photodiode 
array detector. Separately injected 10μl of the standard and the sample preparation in to the 
liquid chromatography and record the area for the major peak. 
The chromatographic conditions described under may be used. 
System  :  waters 2695 
Column  :  A Stainless steel column C18 (250 X 4.6 mm), 5 µm 
Flow Rate  :  1.5ml/min 
Mobile Phase  :  Acetonitrile (600) + Methanol (400)  
Wavelength  :  228 nm 
Injection Volume :   10 µl 
Run Time  :  8 min 
Column Temperature :  48°C 
Sample Report 
Project Name:   PDA2009IInd Reported by User:   System 
Report Method:  Result Set Report Printed 1:56:40 PM11/5/2009
S A M P L E      I N F O R M A T I O N
Sample Name: Acquired By:  System  Blank Glimeperide+Metformine 
Sample Type: Date Acquired: Unknown   11/3/2009 11:03:39 AM  
Vial: Acq. Method Set: 1   MOREPEN 
Injection #: Date Processed: 1   11/5/2009 1:49:51 PM 
Injection Volume: Processing Method: 10.00 ul  GLIMIPEN MF 
Run Time: Channel Name: 8.0 Minutes  2487Channel 1 
Sample Set Name: Proc. Chnl. Descr.: GLIMIPEN MF   228 
AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 
Fig.No. 10 Blank chromatogram of Gluconorm-G1 (Lupin) 
 
 
Fig No. 11 Standard Chromatogram of Gluconorm-G1 (Lupin)
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:23:55 PM11/3/2009
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 1; Date Acquired 11/3/2009 11:12:26 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 2; Date Acquired 11/3/2009 11:21:12 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 3; Date Acquired 11/3/2009 11:29:57 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 4; Date Acquired 11/3/2009 11:38:56 AM
Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 5; Date Acquired 11/3/2009 11:47:42 AM
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Table No. 45 Standard Peak Summary with Statistics of Gluconorm-G1 (Lupin) 
 Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:23:55 PM11/3/2009
1
2
3
4
5
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
2
2
2
2
2
1
2
4
5
3
Glimepiride
Glimepiride
Glimepiride
Glimepiride
Glimepiride
4.022
4.009
3.993
3.989
4.000
4.003
0.013
0.33
200215
201510
200055
203987
200812
201315.8
1599.0
0.8
0.36
0.36
0.36
0.36
0.36
20798
20895
21304
21556
21267
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
3
4
5
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
STD. Glimepiride+Metformine
2
2
2
2
2
1
5
4
3
2
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
Metformine HCl
1.408
1.411
1.410
1.409
1.409
1.409
0.001
0.09
55738711
55925214
55866322
55842572
56047841
55884132.0
113666.4
0.2
99.64
99.64
99.64
99.64
99.64
2844130
2854601
2849064
2846227
2842163
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Fig.No. 12 Assay Chromatogram of Gluconorm-G1 (Lupin) 
 Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:00:36 PM11/5/2009
Sample Name: #J090718 .........Assay ;   Vial: 3; Injection: 1
Sample Name: #J090718 .........Assay ;   Vial: 3; Injection: 2
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Table No. 46 Assay Peak Summary with Statistics of Gluconorm-G1 (Lupin) 
 Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:00:36 PM11/5/2009
1
2
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#J090718 .........Assay
#J090718 .........Assay
3
3
1
2
Glimepiride
Glimepiride
3.980
3.975
3.978
0.004
0.09
178966
177049
178007.6
1355.2
0.8
0.32
0.32
17938
17788
Peak Sum m ary w ith Statistics
Nam e: Glim epiride
1
2
Mean
Std. Dev.
% RSD
Sample
Name Vial Inj Name
Retention
Time (min) Area % Area Height
#J090718 .........Assay
#J090718 .........Assay
3
3
1
2
Metformine HCl
Metformine HCl
1.411
1.411
1.411
0.000
0.02
55610910
55622233
55616571.6
8006.4
0.0
99.68
99.68
2851846
2856570
Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Calculation:
Content Uniformity of Morpean Trial: 
Standard preparation of Glimepiride:  
Weighed and accurately transferred 10.9 mg of Glimepiride working standard into a 
50 ml volumetric flask and make up the volume with mobile phase up to 50 ml, from the 
above stock solution take 5ml in 100 ml volumetric flask and make up the volume with the 
mobile phase. 
Sample preparation of Glimepiride: 
Take 1 intact Bi-layer tablet of Glimepiride and Metformin in 100 ml volumetric 
flask, dissolve in 25 ml of mobile phase make up the volume with mobile phase  
Fig No. 13 Content Uniformity Chromatogram of Morpean Trial 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No. 47 Content Uniformity Peak Summary with Statistics of Morpean Trial 
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Peak Sum m ary w ith Statistics
Nam e: Glim epiride
Peak Summary Report
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Sample Name: #Trial RD .........C.U....1;   Vial: 5; Injection: 1; Date Acquired 11/3/2009 12:31:54 PM
Sample Name: #Trial RD .........C.U....2;   Vial: 6; Injection: 1; Date Acquired 11/3/2009 12:40:43 PM
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Sample Name: #Trial RD .........C.U....7;   Vial: 11; Injection: 1; Date Acquired 11/3/2009 1:24:42 PM
Sample Name: #Trial RD .........C.U....8;   Vial: 12; Injection: 1; Date Acquired 11/3/2009 1:33:30 PM
Sample Name: #Trial RD .........C.U....9;   Vial: 13; Injection: 1; Date Acquired 11/3/2009 1:42:19 PM
Sample Name: #Trial RD .........C.U....10;   Vial: 14; Injection: 1; Date Acquired 11/3/2009 1:51:06 PM
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Calculation:
Assay of Morepen Trial-5: 
Standard preparation of Glimepiride:  
Weighed and accurately transferred 11.0 mg of Glimepiride and 495.6 mg of 
Metformin working standard into a 100 ml volumetric flask and make up the volume with 
mobile phase up to 100 ml 
Sample preparation of Glimepiride:  
Weighed accurately 20 tablets each containing 500mg Metformin and 1 mg 
Glimepiride crush them in to fine powder. Weight equivalent to Metformin and Glimepiride, 
transfer the powder to 100 ml volumetric flask. Filter the solution through 0.45 µ GFC filter 
paper  
Procedure: Assay was carried out in HPLC (water system) including pump, photodiode 
array detector. Separately injected 10μl of the standard and the sample preparation in to the 
liquid chromatography and record the area for the major peak. 
The Chromatographic conditions described under may be used. 
System  :  Waters 2695 
Column  :  A Stainless steel column C18 (250 X 4.6 mm), 5 μm 
Flow Rate  :  1.5 ml/min 
Mobile Phase  :  Acetonitrile (600) + Methanol (400)  
Wavelength  :  228 nm 
Injection Volume :   10 µl 
Run Time  :  8 min 
Column Temperature :  48°C 
Fig. No. 14 Blank Chromatogram of Morpean Trial 
 
Sample Report 
Project Name:   PDA2009IInd Reported by User:   System 
Report Method:  Result Set Report Printed 1:56:40 PM11/5/2009
S A M P L E      I N F O R M A T I O N
Sample Name: Acquired By:  System  Blank Glimeperide+Metformine 
Sample Type: Date Acquired: Unknown   11/3/2009 11:03:39 AM  
Vial: Acq. Method Set: 1   MOREPEN 
Injection #: Date Processed: 1   11/5/2009 1:49:51 PM  
Injection Volume: Processing Method: 10.00 ul  GLIMIPEN MF 
Run Time: Channel Name: 8.0 Minutes  2487Channel 1 
Sample Set Name: Proc. Chnl. Descr.: GLIMIPEN MF   228 
AU 
0.00 
0.50 
1.00 
1.50 
2.00 
Minutes
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 
Fig No. 15 Standard Chromatogram of Morpean Trial 
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Sample Name: STD. Glimepiride+Metf ormine;   Vial: 2; Injection: 5; Date Acquired 11/3/2009 11:47:42 AM
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Table No. 48 Standard Peak Summary with Statistics of Morpean Trial 
Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:23:55 PM11/3/2009
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Peak Sum m ary w ith Statistics
Nam e: Glim epiride
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Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
Fig. No. 16 Assay Chromatogram of Morpean Trial 
Peak Summary Report
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Table No. 49 Assay Peak Summary with Statistics of Morpean Trial 
 Peak Summary Report
Project Name:    PDA2009IIndReported by  User:    Sy stem
Report Method:  Peak Summary  Report Printed 2:29:49 PM11/3/2009
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Peak Sum m ary w ith Statistics
Nam e: Metform ine HCl
 
Calculation:  
IN VITRO DISSOLUTION TEST (By U.V) 
Comparative study of innovator product and optimization formulation 
 
Dissolution of Metformin drug: 
Dissolution study of tablet performed in USP II (Paddle) dissolution test apparatus 
(Electro lab TDT 08L) using 900ml of Phosphate buffer as a dissolution media. The tablet 
was loaded in to each basket of dissolution apparatus; the temperature of dissolution media 
was maintained at 37°C ± 0.5°C with stirring speed of 100 rpm through out the study. 
Aliquots of dissolution media containing 10 ml of sample were taken at time interval of 1, 2, 
4, 6, 8 hours and 10 ml of fresh dissolution media maintaining at the same temperature was 
replace after each withdrawal. The samples were analyzed by U.V Spectroscopy at 232nm. 
The raw dissolution data was analyzed for calculating the amount of drug released and 
percentage cumulative drug release at different time intervals. 
Dissolution Parameters: 
Medium            :  6.8 gm of Ortho-Phosphoric acid Solution (6.8mg in 1000 ml ).  
  Adjust to pH 6.8 by NaOH.  
Quantity            :  900 ml 
Apparatus         :  Apparatus II (Paddle). 
rpm  : 100 
Time                 :  1, 2, 4, 6, & 8 hours or required intervals. 
Temperature     :  37 ± 0.5ºC. 
 
Preparation of 6.8-pH Phosphate Buffer Medium: 
6.8 gm of Ortho-Phosphoric acid added to the 1000 ml volumetric flask and make up 
the volume with 1000 ml-Distilled water  
 
 
Standard Solution Preparation: 
 
Take 25 mg of Metformin working standard into 50 ml volumetric flask, dissolve and 
make up to the volume with distilled water, from that take 2 ml of sample and again 
dissolved in to 50 ml of Distilled water. 
Taken the absorbance at 232 nm of the prepared samples in U.V spectrophotometer  
 
Sr. No Concentration (μg/ml) Absorbance 
(nm) 
1. 2.5 0.285 
2. 5 0.475 
3. 7.5 0.682 
4. 10 0.851 
5. 12.5 1.067 
6. 15 1.240 
 
 
 
 
Fig No.17 Standard curve of Metformin 
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Where:  
 
W1 = Weight of working standard 
L.C =  Label claim in mg 
P1 = % potency of working standard 
AS =  Absorbance of the Metformin standard sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No. 50 Dissolution Study of Metformin (USV) 
 
Absorbance x 
factor  
(% release) 
% Release 
after 1 
hour 
% Release 
after 2 hour 
% Release 
after 4 hour 
% Release 
after 6 hour 
% Release 
after 8 hour 
A1 x F 39.15 60.3 68.5 78.62 89.81 
A2 x F 41.59 61.19 71.49 79.89 90.6 
A3 x F 42.87 58.58 72.18 79.52 89.41 
A4 x F 36.31 59.97 71.35 81.85 90.62 
Average 39.98 60.01 70.88 79.97 90.11 
 
 
Fig.No. 18 Dissolution Profile of Glycomet GP-1mg (USV) 
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Table No. 51 Dissolution study of Gluconorm-G1 (Lupin) 
 
Absorbance 
x factor  
(% release) 
% Release 
after 1 hour 
% Release 
after 2 hour 
% Release 
after 4 hour 
% Release 
after 6 hour 
% Release 
after 8 hour 
A1 x F 39.24 58.57 70.25 79.64 90.25 
A2 x F 42.16 60.35 69.46 80.11 92.36 
A3 x F 38.53 61.01 71.25 81.37 90.47 
A4 x F 40.55 62.27 70.58 82.04 91.58 
Average 40.12 60.55 70.38 80.79 91.16 
 
 
Fig. No. 19 Dissolution Profile of Gluconorm-G1 (Lupin) 
 
 
 
 
 
Table No.  52 Dissolution Study of Trial-5 (Morpean lab.) 
 
Absorbance x 
factor(% 
release) 
% Release 
after 1 hour 
% Release 
after 2 hour 
% Release 
after 4 hour 
% Release 
after 6 hour 
% Release 
after 8 hour 
A1 x F 46.09 58.53 71.56 82.63 92.39 
A2 x F 46.09 62.97 71.37 82.6 97.06 
A3 x F 45.09 63.52 72.85 83.67 92.41 
A4 x F 45.31 64.86 74.3 83.62 93.62 
Average 45.64 62.47 72.52 83.13 93.87 
 
 
Fig. No. 20 Dissolution Profile of Trial- 5 (Morpean) 
 
 
 
 
 
Calculation of Dissimilarity (f1) and Similarity (f2) factor: 
Dissimilarity factor: 
It was calculated in the comparison with reference or innovator product to know the 
dissimilarity  
The dissimilarity factor (f1) should be always less then 15(f1< 15) 
 
 
Similarity factor (f2): 
The similarity factor (f2) was defined as the logarithm reciprocal square root 
transformation of one plus the mean squared difference in percent dissolved between the test 
and the reference products. This was calculated to compare the test with reference release 
profiles 
The Similarity factor (f2) should be always greater then 50 (f2 >50) 
The method is more adequate to compare dissolution profile when more than three or 
four dissolution time points are available and can only be applied if average difference 
between Rt and Tt is less then 100. If this difference is higher than 100, normalization of data 
is required. 
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Conclusion: 
Tablet No.  53 for Metformin  
Time(hours) Rt1 
USV 
Rt2 
LUPIN 
Tt Rt1-Tt Rt2-Tt ∑(Rt1-
Tt)2 
∑(Rt2-
Tt)2 
1 39.98 40.12 45.64 -5.66 -5.52 32.035 30.4704 
2 60.01 60.55 62.47 -2.46 -1.92 6.0516 3.6864 
4 70.88 70.38 72.52 -1.64 -2.14 2.6896 4.5796 
6 79.97 80.79 83.13 -3.16 -2.34 9.9856 5.4756 
8 90.11 91.16 93.87 -3.76 -2.71 14.137 7.3441 
Average ∑340.95 ∑343  ∑-16.68 ∑-14.63 ∑64.8988 ∑51.5561
 
  
  
 
  
 
 
Comparative Dissolution Profile of Metformin Drug 
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 Fig.No. 21Comparative Dissolution Profile of Metformin Drug 
 
Stability Study 
The stability with respect to the Dosage from refer to the Chemical and physical integrity of 
the damage form and stability of the dosage form to maintain protection against 
microbiological contamination. 
It is also defined as the time laps during which drug retains same physical and chemical 
properties those possess at the time of manufacturing. 
The main purpose of conducting stability testing for Pharmaceutical Product:  
• To ensure the efficacy, safety and Quality testing of active drug substance and dosage  
form 
• To establish Shelf Life or Expiration Period 
• To support label claim 
ICH Guidelines for Stability Testing: 
The International Conference on Harmonization (ICH) brings together experts from 
Pharmaceutical and regulatory authorities of Europe, Japan and other countries to discuss 
scientific and technical aspects of product registration. Whole world is divided into four 
climatic zone in order to harmonize and simplify the stability testing. 
Table No. 54 List of Countries according to Climatic Zone 
Regions Zone I & Zone II Zone III & Zone IV 
Europe All countries  
America Canada, Mexico United states Brazil, Jamaica, Cuba 
Asia Afghanistan, China, Japan, Korea, Iran, Israel, Turkey 
Hong Kong, Bangladesh, India, 
Pakistan, Singapore, Saudi 
Arabia 
Africa Egypt, South Africa, Zimbabwe Kenya, Libya, Sudan, Nigeria 
Australia 
Ocean Australia, New Zeeland Fiji Tonga 
Table No. 55 
Worldwide zones and the Temperature and Humidity conditions as per ICH Guidelines 
Zones Mean Kinetic 
Temperature 
Yearly Average Humidity
Zone I(Temperate) 21°C 45% 
Zone II(Mediterranean) 25°C 60% 
Zone III(Hot & Dry) 30°C 35% 
Zone IV(Hot & Humid) 80°C 70% 
The recommended storage test condition for different types of stability studies is given as in 
following manner: 
Table.No.56 
Intended storage condition of finished production 
Study  
Room Temp 
Refrigerator 
(general case) Freezer 
Maximum 
periods 
Covered by 
data at 
Submission 
Long term 
study 
25 ± 2°C/60± 5%R.H. 
Or 
30 ± 2°C/60 ± 5%R.H. 
5 ± 3°C -20±5°C 12 Months 
Intermediate 
Stability Study 30 ± 2°C/60 ± 5%R.H. -- -- 6 Months 
Accelerated 
Stability Study 40 ± 2°C/5 ± 5%R.H. 
If available 
25 ±2°C/60±5%R.H. 
otherwise 
30±2°C/65±5%R.H. 
-- 6 Months 
 If 30°C / 65% R.H.is the long term stability condition, there are no intermediate 
conditions 
Acceptance criteria for stability study at the point of data submission 
¾ For each test included in the product, a suitable acceptance criterion should be fixed. 
¾ The criteria for quantitative result will be in the term of numerical limits i.e. 
dissolution rate drug assay in terms of % for solids and water loss in term of liquids. 
¾ For quantitative tests, the criteria may be in the term of pass or fail. 
According to ICH Guidelines “Significant changes” in accelerated stability study is defined 
as- 
¾ 5% potency loss from the initial assay value of a batch. 
¾ Specified degradation product exceeding its acceptable criteria. 
¾ Failure to meet specification for appearance, physical properties and functionality 
test. 
¾ Failure to meet specification limit for pH 
¾ Failure to meet specification limit for dissolution of tablets. 
¾ A 5% loss in water from its initial value is considered a significant change for a 
product packaged in semi permeable container, intended to be stored at room 
temperature, refrigerator and freezer.  
Testing Frequency: 
¾ According to ICHQ1A and CPMP- QWP/556/96 Guidelines for real time testing 
during first year sampling should be done for every six months and after two years 
sampling should be done in a year. 
¾ Accelerated testing should be done for at least 6 month according to ICHQ1A,and 
sampling point of 0, 3 & 6 months, whereas WHO Guidelines suggest 0, 1, 2, 3 & 6 
months sampling Intervals. 
¾ For intermediate testing, according to ICHQ1A sampling intervals are 0, 6, 9, 12 
months. 
Test Procedure and Test Criteria:  
The Stability Assay is conducted by keeping the drug substance or the product in final 
containers or packing and under the selected storage conditions. Samples are withdrawn at 
the prescribed sampling intervals  and subjected to analysis, sampling for analysis are 
generally taken from previously unopened containers, however samples can be taken from 
previously opened containers in case of products packaged in unit of use of containers 
intended for  dispensing to multiple patients or for repacking. The dosage units should be 
sampled from the container randomly with each dosage form unit having an equal chance of 
being included in the sample  
Evaluation:  
A systemic approach should be adopted in the presentation and evaluation of the 
stability information, which should include results from the chemical, physical and 
microbiological tests including particular attributes of the dosage form 
Accelerated Stability Study:  
Table No.57 Stability data for Exposing sample at 40°C / 75% R.H for 1 month 
Sr. No. Testes Observation 
1. Color No Change  
2. Moisture Content 3.21 
3. Impurity No 
4. Assay (Metformin) 98.48 
5. Assay (Glimepiride) 98.16 
 
Table No.58 Dissolution Profile for Exposed sample at 40°C/75 % R.H. for 1 Month 
Time(hours) % Drug Release of Metformin 
1 40.12 
2 60.55 
4 70.38 
6 80.79 
8 91.16 
 
Table No.59 Stability data for Exposing at 25°C / 60% R.H for 1 month 
Sr. No. Testes Observation 
1. Color No Change 
2. Moisture Content 3.38 
3. Impurity No 
4. Assay (Metformin) 99.60 
5. Assay (Glimepiride) 99.42 
 
Table No. 60 Dissolution Profile for Exposed sample at 25°C/60 % R.H. for 1 Month 
 
Time(hours) % Drug Release of Metformin 
1 45.52 
2 62.38 
4 72.45 
6 83.08 
8 92.87 
Results and Discussion 
1. Preformulation Study: 
 The present investigation was carried out to develop Bi-layer tablet dosage form of 
Metformin and Glimepiride drug. The tablets are prepared by using different excipients. 
1.1 Compatibility Study:  
Drug: Excipients Compatibility study of Metformin and Glimepiride with different 
categories of excipients was carried out. The study was carried out at different conditions of 
temperature and humidity like 40°C / 75% R.H., 2-8°C, at room temperature and noted their 
physical appearance, impurity level and water content after 2 weeks, 4weeks, and compared 
with initial value as shown in Table No. 29 & 30. Organoleptic properties of drug in 
presence of excipients was carried out at different interval and compared with initial color as 
shown in Table No. 31 & 32 
2. API  Characterization Study : 
 
2.1 Sieve Analysis of API: 
 The sieve analysis carried out by using mechanical shaker, the particle size of 
Metformin and Glimepiride were analyzed separately on Electromagnetic sieve shaking and 
weighing of the portion of the sample retained on each sieve and calculated percentage 
retained on each sieve Table No. 17, 18 & 19 
2.2 Powder Flow Properties: 
 The Metformin and Glimepiride drug show poor flow properties. In order to 
overcome this direct compression Technique was adopted and the result of improved flow 
shown in Table No. 7 & 8 indicates that drug has improved flow property. 
 
3.  Evaluation of Formulation Parameters: 
Evaluation was divided mainly in to: 
- Pre-Compression Parameters 
- Post Compression Parameters  
 Pre compression parameters include loss on drying of dried granules and final blend, 
Bulk density, Tapped Density, Carr’s Index, Housner’s ratio and sieve analysis. In post 
compression parameters Average Weight, Thickness, Hardness, Disintegration Time and 
Friability were determined. 
3.1 Pre Compression  Parameters:  
Loss on drying (LOD):  
 Sample of Metformin blend was kept in an oven at 60°C for 2 hours and decrease in 
weight of sample were observed. Sample of Metformin blend was kept in an oven at 40° C 
for 2 hours and decrease in weight of sample was observed. Usually 3 samples are taken to 
observe the Loss on Drying as shown in Table No. 21 shows for % LOD in a particular limit. 
Powder Flow Characteristics:  
The flow characteristics of final blend of both Metformin and Glimepiride drug was 
shown in Table No. 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 & 16 
¾ Bulk density for Metformin and Glimepiride in the range of  0.465-0.530 gm/ml 
¾ Tapped density in the range 0.572 – 0.633 gm/ml 
¾ Carr’s index ranging 17.98- 20.09 %  
¾ Hausner’s ratio in the range 1.21-1.25 shows the good flow characteristics. 
 
 
3.2 Post Compression Parameters: 
Weight Variation: 
 In Trial 1-5, weight variation was determined given in Table No. 36, but in final trial 
tablet ranging 1100.85 mg (Average weight -1100 mg /tab), which is less than 5%, indicate 
that the variation in the weight of the tablets is within standard official limits. 
Thickness Evaluation:  
 Thickness of tablets was carried out by Vernier calipers. Thickness of tablets shows 
very slight deviation in both strengths given in Table No. 37  
Hardness Test:  
 Hardness of the tablets was measured in Newton (N) unit in digital hardness tester. 
The hardness of tablets found to be uniform within range given in Table No. 38 indicates 
that the prepared tablets are mechanically stable. 
Friability Test:  
 The friability was carried out by using Roche Friabilator. The % friability of tablets 
was ranging 0.11-0.14 % for 1100.85 mg tablet and given in Table No.39 they are less than 
the standard limit of 1% indicates that the prepared tablets are mechanically stable.  
Drug Content Uniformity:  
 The drug uniformity of Glimepiride found in given limit in ranging from 95-105 %, 
which is within the range of 95.43-105.4 %. It indicates uniformity distribution of drug in the 
table of each formulation. 
 
 
In vitro Drug release Studies: 
 Dissolution study of Metformin performed in USP-II (Paddle) Dissolution test 
apparatus (Electro lab TDT08L) using 900ml of acetate buffer as a dissolution media. The 
tablets was loaded into an each basket of dissolution apparatus, the temperature of dissolution 
media was maintained at 37°C with stirring speed 100 rpm throughout the study. As show in 
Table No.52 
F2 Value:  
 Similarity factor (F2) was calculated between innovator formulation and our 
formulation. Similarity factor value in the range of 50-100 indicates that there is similarity in 
the release profile of the formulations. 
 F2 Value of both Metformin and Glimepiride was found to be satisfactory, as F2 
values for Metformin is 78.24 respectively given in Table No.53 and Figure No.21 Show the 
dissolution profile. 
4. Stability Study:  
 The stability studies of final trial was done for 3 months by packing in high density 
polyethylene (HDPE) container in humidity chamber (40°C/75%RH) 
 The results given in Table No. 57, 58, 59 & 60 for 1 month, show all parameters of 
formulation including physical parameters, impurity profile, content uniformity and 
dissolution profile were within specification limit. So therefore it indicates that optimization 
formulations were stable. 
Conclusion 
¾ Drug excipients compatibility study with Metformin-Glimepiride was conducted with 
different excipients and compatible excipients were used. 
¾ Trial –V that compose of Metformin, Glimepiride, MCC Rank-Q-102, Colloidal 
Silicon Dioxide, Hydroxyl Propyl Methyl Cellulose, Magnesium Stearate and Starch, 
shows better compatibility. 
¾ The result of this study shows that in case of all tablets formulation, the trial –V 
formulation shows better results in pre-compression as well as in post compression 
parameters 
¾ Trial-V also shows better Metformin-release profile in phosphate buffer media  
¾ In the stability study under storage condition 40oC/75%RH after 1 month shows that 
the formulation trial –V has better result under official limit for pre-compression and 
post compression parameters. 
¾ The optimized Metformin and glimepiride Bi-layer tablet satisfies the entire official 
requirement for a generic product, which is found not only stable but also comparable 
with innovator product 
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